Polycyclic indole derivatives as novel structures for neuroprotection

Dissertation submitted in partial fulfilment of the requirements for the degree

MAGISTER SCIENTIAE

in

the Department of Pharmaceutical Chemistry

at the North-West University, Potchefstroom Campus

By

Armand de Vries

December 2006

Supervisor: Prof S.F. Malan
Co-supervisor: Prof D.W. Oliver
CHAPTER 1: INTRODUCTION

1.1. Background ................................................................. 1
1.2. Antioxidants ............................................................ 1
1.3. Enzyme inhibition ......................................................... 3
1.4. Compounds for synthesis ................................................ 5
1.5. Aim of study ............................................................. 6

CHAPTER 2: MECHANISMS IN NEURODEGENERATION

2. Introduction .................................................................. 7
2.1. The lethal triplet ........................................................... 7
2.1.1. Metabolic compromise ............................................... 8
2.1.2. Excitotoxicity ............................................................ 8
2.1.3. Oxidative stress ........................................................ 11
2.2. NMDA receptor in neurodegeneration ............................. 13
2.3. Neuroprotective strategies .............................................. 16
2.3.1. Attenuation of excitotoxicity ........................................ 17
2.3.2. Calcium channel blockage and calpain inhibition .......... 18
2.3.3. Reactive oxygen and nitrogen scavengers .................... 18
2.3.4. Superoxide scavenging .............................................. 19
2.3.5. Inhibition of caspases and pro-apoptotic cascades .......... 19
2.4. Enzyme inhibition ....................................................... 19
2.4.1. Nitric oxide synthase ................................................ 19
Table of contents

2.4.2. Structure ................................................................. 20
2.4.3. NOS isoforms .......................................................... 22
2.4.4. NOS Inhibitors ......................................................... 23
2.5. Polycyclic amines and indole derivatives ......................... 34
2.6. Conclusion ................................................................. 35

CHAPTER 3: MOLECULAR MODELLING

3. Introduction ............................................................................. 37
3.1. The substrate binding site of nNOS ........................................... 37
  3.1.1. Molecular recognition of 3-Br-7-NI at the substrate binding ..... 38
  3.1.2. Implications of the binding site of NOS for drug design ........... 40
3.2. Methodology ........................................................................... 41
3.3. Results and Discussion .......................................................... 47
3.4. Conclusion .............................................................................. 49

CHAPTER 4: SYNTHETIC PROCEDURES

4. Instrumentation ......................................................................... 50
  4.1. Chromatographic methods ..................................................... 50
  4.2. Selection of compounds ........................................................ 51
  4.3. General synthetic route .......................................................... 52
    4.3.1. Pentacyclo[5.4.0.0²6.3⁰10.0⁶₉]undecane-8,11-dione (A) .......... 53
    4.3.2. Pentacyclo[5.4.0.0²6.3⁰10.0⁶₉]undecane-8-one (J) ............... 54
    4.3.3. 8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.0²6.0⁴₁₀.0⁶₉]undecane-11-
            one ................................................................. 55
    4.3.4. 8-[3-(2-aminoethyl)indole]-8,11-oxapentacyclo[5.4.0.0²6.0³₁₀.0⁶₉]undecane ....... 56
    4.3.5. 3-hydroxy-4-[3-(2-aminoethyl)indole]-azahexacyclo
            [5.4.1.0²₆.0³₁₀.0⁶₉.0⁶₁₁]dodecane ................................ 56
    4.3.6. 8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.0²₆.0³₁₀.0⁶₉]undecane .... 57
## Table of contents

4.3.7. 8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0^2.6.0^3.10.0^5.9]undecane … 58

4.3.8. Additional cage structures …………………………………………………………………………………… 59

4.3.9. 8-Ethoxy-8-ethylamino-pentacyclo[5.4.0^2.6.0^3.10.0^5.9]undecane-11-one …………………………………… 63

4.4. Conclusion and Discussion: …………………………………………………………………………………………… 64

### CHAPTER 5: BIOLOGICAL EVALUATION

5. Nitric oxide synthase determination ………………………………………………………………………………… 65

5.1. Introduction ………………………………………………………………………………………………………………… 65

5.2. Experimental procedures ……………………………………………………………………………………………… 70

5.2.1. Materials ………………………………………………………………………………………………………………… 70

5.2.2. Methods ………………………………………………………………………………………………………………… 72

5.2.3. Results and Discussion …………………………………………………………………………………………….. 73

5.3. Lipid peroxidation ………………………………………………………………………………………………………… 83

5.3.1. Introduction ……………………………………………………………………………………………………………… 83

5.3.2. Experimental procedures …………………………………………………………………………………………… 85

5.3.3. Assay procedure ……………………………………………………………………………………………………… 86

5.3.4. Results and Discussion …………………………………………………………………………………………….. 87

5.4. Conclusion ………………………………………………………………………………………………………………… 89

### CHAPTER 6: SUMMARY, DISCUSSION AND CONCLUSION

6. Introduction ………………………………………………………………………………………………………………… 91

6.1. Molecular modelling …………………………………………………………………………………………………… 91

6.2. Synthesis ………………………………………………………………………………………………………………… 92

6.3. Biological evaluation …………………………………………………………………………………………………… 92

6.4. Conclusion ………………………………………………………………………………………………………………… 93

7. Bibliography: ………………………………………………………………………………………………………………… 95

ANNEXURE 1 ………………………………………………………………………………………………………………….. 114
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD</td>
<td>Parkinson’s disease</td>
</tr>
<tr>
<td>SAR</td>
<td>Structure-activity relationships</td>
</tr>
<tr>
<td>O₂</td>
<td>Oxygen</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>LMWA</td>
<td>Low molecular weight antioxidants</td>
</tr>
<tr>
<td>SOD</td>
<td>Superoxide dismutase</td>
</tr>
<tr>
<td>OS</td>
<td>Oxidative stress</td>
</tr>
<tr>
<td>NADPH</td>
<td>Nicotinamide adenine dinucleotide phosphate</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>BBB</td>
<td>Blood-brain barrier</td>
</tr>
<tr>
<td>NMDA</td>
<td>N-methyl-D-aspartate</td>
</tr>
<tr>
<td>nNOS</td>
<td>Neuronal nitric oxide synthase</td>
</tr>
<tr>
<td>MAO-B</td>
<td>Monoamine oxidase oxidase B</td>
</tr>
<tr>
<td>MPTP</td>
<td>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</td>
</tr>
<tr>
<td>MPP⁺</td>
<td>1-Methyl-4-phenylpyridinium</td>
</tr>
<tr>
<td>7-NI</td>
<td>7-nitroindazole</td>
</tr>
<tr>
<td>MPDP⁺</td>
<td>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</td>
</tr>
<tr>
<td>DA</td>
<td>Dopamine</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>TBA</td>
<td>Thiobarbituric acid</td>
</tr>
<tr>
<td>NOS</td>
<td>Nitric oxide synthase</td>
</tr>
<tr>
<td>3-NP</td>
<td>3-nitropropionic acid</td>
</tr>
<tr>
<td>MA</td>
<td>Malonic acid</td>
</tr>
<tr>
<td>HD</td>
<td>Huntington’s disease</td>
</tr>
<tr>
<td>EAA</td>
<td>Excitatory amino acid</td>
</tr>
<tr>
<td>RNS</td>
<td>reactive nitrogen species</td>
</tr>
<tr>
<td>AMPA</td>
<td>α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid</td>
</tr>
<tr>
<td>KA</td>
<td>Kainate</td>
</tr>
<tr>
<td>NO</td>
<td>nitric oxide</td>
</tr>
<tr>
<td>mGluR</td>
<td>metabotropic glutamate receptor</td>
</tr>
<tr>
<td>PL</td>
<td>phospholipidsPLA₂, phospholipase A₂</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>DAG</td>
<td>Diacylglycerol</td>
</tr>
<tr>
<td>PLC</td>
<td>Phospholipase C</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein kinase C</td>
</tr>
<tr>
<td>G</td>
<td>G protein</td>
</tr>
<tr>
<td>PIP₂</td>
<td>Phosphatidylinositol 4,5-bisphosphate</td>
</tr>
<tr>
<td>IP₃</td>
<td>Inositol 1,4,5-trisphosphate</td>
</tr>
<tr>
<td>H₂O₂</td>
<td>Hydrogen peroxide</td>
</tr>
<tr>
<td>VSCC</td>
<td>Voltage-sensitive Ca²⁺ channel</td>
</tr>
<tr>
<td>•OH</td>
<td>Hydroxyl radical</td>
</tr>
<tr>
<td>ONOO⁻</td>
<td>Peroxynitrite</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>PARS</td>
<td>Poly ADP ribosyl synthase</td>
</tr>
<tr>
<td>PARP</td>
<td>Poly ADP ribosyl polymerase</td>
</tr>
<tr>
<td>NAD</td>
<td>Nicotinamide adenine dinucleotide</td>
</tr>
<tr>
<td>HNE</td>
<td>4-Hydroxynonenal</td>
</tr>
<tr>
<td>SNO</td>
<td>Cysteine sulfhydryl group</td>
</tr>
<tr>
<td>CTD</td>
<td>Carboxyl terminal domain</td>
</tr>
<tr>
<td>PCP</td>
<td>Phencyclidine</td>
</tr>
<tr>
<td>TBI</td>
<td>Traumatic brain injury</td>
</tr>
<tr>
<td>CDPC</td>
<td>Cytidine 5'-diphosphocholine</td>
</tr>
<tr>
<td>eNOS</td>
<td>Endothelial nitric oxide synthase</td>
</tr>
<tr>
<td>iNOS</td>
<td>Inducible nitric oxide synthase</td>
</tr>
<tr>
<td>H₂B</td>
<td>Biopterin</td>
</tr>
<tr>
<td>TRIM</td>
<td>1-(2-Trifluoromethylphenyl) imidazole</td>
</tr>
<tr>
<td>DDAH</td>
<td>Dimethylarginine dimethylaminohydrolase</td>
</tr>
<tr>
<td>AD</td>
<td>Alzheimer's disease</td>
</tr>
<tr>
<td>3-Br-7-NI</td>
<td>3-Bromo-7-nitroindazole</td>
</tr>
<tr>
<td>L-Arg</td>
<td>L-arginine</td>
</tr>
<tr>
<td>SD</td>
<td>Structural data</td>
</tr>
<tr>
<td>L-NHA</td>
<td>N⁶-Hydroxy-L-arginine</td>
</tr>
<tr>
<td>EI</td>
<td>Electron ionisation</td>
</tr>
<tr>
<td>HRMS</td>
<td>High resolution mass spectrometry</td>
</tr>
<tr>
<td>IR</td>
<td>Infrared</td>
</tr>
<tr>
<td>TLC</td>
<td>Thin layer chromatography</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>Definition</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>NBT</td>
<td>Nitro blue tetrazolium</td>
</tr>
<tr>
<td>OxyHb</td>
<td>Oxyhemoglobin</td>
</tr>
<tr>
<td>methHb</td>
<td>Methemoglobin</td>
</tr>
<tr>
<td>PUFAs</td>
<td>Polyunsaturated fatty acids</td>
</tr>
<tr>
<td>MDA</td>
<td>Malondialdehyde</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate-buffered saline</td>
</tr>
</tbody>
</table>
The lethal triplet of metabolic compromise, excitotoxicity and oxidative stress causes neuronal cell death that is both necrotic and apoptotic in nature. Aspects of each of these mechanisms are believed to play a role in the neurodegeneration that occurs in both Parkinson's and Huntington's diseases.

The overstimulation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors is involved in excitotoxicity, a process in neurodegeneration that characterises some neurological disorders and acute cerebral insults. In this process excess NO formation and oxidative stresses are key factors. In searching for compounds with neuroprotective properties, a series of tryptamine derivatives were synthesised and their effects were evaluated on both NOS and lipid peroxidation activity.

Computer modelling was performed using Catalyst 4.9® and the Ligandfit module of Cerius2® to determine the feasibility for synthesis and biological evaluation of the novel compounds. The hydrogen bond network formed in the enzyme was used as an indication for possible inhibitory activity. H-bonds with Tpr587, Glu592 and heme were taken as essential for NOS activity. Hydrogen bonds with Tyr588, Gln478 and Asp597 could also be important, since these amino acids play a role in the stabilisation and orientation of ligands in the cavity. The molecular modelling study indicated that the novel compounds were potential candidates for future investigation in view of their interaction at the NOS active site.

Compounds were synthesised by reductive amination or activation chemistry with various linkers. Novel rearranged polycyclic structures were obtained when linkers were applied. Difficulties were experienced with yields, purification and isolation of the compounds and could be attributed to solubility and multiple reactions taking place. Selected compounds were characterised and evaluated for NOS and antioxidative properties.

The oxyhemoglobin assay was employed to determine the NOS activity of the polycyclic indole derivatives. Results from the assay showed that four compounds, containing the indole moiety, 8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.0°.0°.0°.0°.0°]undecane-11-one (1), 3-hydroxy-4-[3-(2-aminoethyl)indole]-azahexacyclo[5.4.1.0°.0°.0°.0°.0°]undodecane (3), 8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0°.0°.0°.0°.0°]undecane (4) and 8-[3-(2-
aminoethyl)indole]-pentacyclo[5.4.0\(2^6.0^3\{10.0^5\{6\]\}undecane (5) displayed potencies in the sub millimolar range. Compounds such as 19 and 21 that do not possess an indole moiety, were poor inhibitors of NOS.

From the lipid peroxidation study, compounds 1, 2, 3, 4 and 5 showed antioxidative properties comparable to that of trolox.

The results obtained in this study clearly indicate the potential of these novel indole cage structures as NOS inhibitors and anti-oxidants.

Taking the above aspects into account, together with the described calcium channel activity of the cage structures, these novel compounds may find applications as multipotent drugs in neuroprotection.
Die letale triplet bestaande uit metaboliëse afwyking, eksitotoksiteit en oksidatiewe skade lei tot seldood wat nekroties en/of apoptoties van aard is. Elkeen van hierdie drie mekanismes speel 'n rol in neurodegenerasie en kom voor in Parkinson en Huntington se siekte.

Oorstimulasie van die M-metiel-D-aspartaat (NMDA) reseptore is betrokke by eksitotoksiteit, 'n proses in neurodegenerasie wat sommige neurologiese siektes en akute serebrale skade karakteriseer. Oormatige produksie van stikstofoksied (NO) en oksidatiewe skade is sleutelfaktoore tydens hierdie proses. In die soeke na verbondings met neurobeskermende eienskappe is 'n reeks tryptamienderivate gesintetiseer en gævalueer vir inhibisie van stikstofoksiedsintetase (NOS) en lipiedperoksidadse.

Molekuliëre modellering is uitgevoer met Catalyst 4.9 en die Ligandfit-module van Cerius2 om te bepaal of dit sinvol sou wees vir die sintese en biologiese evaluering van die nuwe verbondings. Die waterstofbindingsnetwerk wat gevorm het in die ensemi is gebruik as 'n indikasie vir moontlike inhibitoriese aktiwiteit. Waterstofbindings met Tpr587, Glu592 en heem is as essensieel geag vir NOS-aktiwiteit. Waterstofbindings met Tyr 588, Gln 478 en Asp 597 is ook van belang, aangesien dieselfde aminosure 'n rol speel by die stabilisering en oriëntasie van ligande in die aktiewe setel. Na aanleiding van hul interaksies by die NOS ensiem, toon hierdie verbondings potensiaal as NOS inhibeerders.

Die verbondings is gesintetiseer deur reduktiewe aminering of aktiveringschemie met verskeie skakels. Nuwe herrangskikte polisikliese strukture is verkry in die geval. Probleme is ondervind met die opbrengste, suiwering en isolering van die verbondings en kan toegeskryf word aan oplosbaarheid en meervoudige reaksies wat plaasgevind het.

Die oksihemoglobientoets is gebruik om die NOS aktiwiteit van die polisikliese indooldervate te bepaal. Die resultate het getoon dat vier verbondings wat die indooldentiteit besit, 8-[3-(2-amino-etiel)indoold-pentasiklo[5.4.0.02.8.03.10.05.8]undekan-11-oon (1), 3-hidroksi-4-[3-(2-amino-etiel)indoold-azaheksasiklo[5.4.1.02.8.03.10.05.9.08.11]dodekan (3), 8-[3-(2-amino-etiel)indoold-pentasiklo[5.4.0.02.8.03.10.05.8]undekan (4) en 8-[3-(2-amino-etiel)indoold-pentasiklo[5.4.0.02.8.03.10.05.8]undekan (5), aktiwiteit in millimol6re konsentrasie besit. Verbindings soos 19 en 21 wat nie die indooldentiteit besit nie, is swak inhibeerders van NOS.
Die lipiedperoksidasiestudie het getoon dat die indoolverbinding 1, 2, 3, 4 en 5 anti-oksidatiewe eienskappe besit wat vergelykbaar is met trolox.

Die resultate verkry in hierdie studie beklemtoon die potensiaal van die nuwe indoolhokverbinding as NOS inhibeerders en anti-oksidante. Met die bekende kalsiumkanaal aktiwiteit van die hokstrukture en die bogenoemde aktiwiteite kan die nuwe verbinding toepassings as multipotente middels in neurobeskerming vind.
1.1. Background

Neurodegeneration and subsequent neuronal death account for the clinical manifestations of many different neurological disorders of aging, including Alzheimer's disease, Parkinson's disease and stroke. These disorders are of vast concern for the modern population and have thus raised great interest in this field.

Drug design plays a pivotal role in the attenuation of these disorders due to the fact that the cause of neurodegeneration in PD remains unresolved and debatable. Computer modelling has been developed to increase the likelihood of discovering new potential pharmacologically active compounds. Rational drug design is based on the principle that biological properties of molecules are related to their actual structure. SAR evaluation of a series of homologous compounds, derived from a lead compound, may uncover a desired pharmacologically active compound that can be used as drug or lead in further studies.

Most diseases are induced by more than one pathogenic factor and therefore the current drug discovery paradigm is shifting from addressing single molecular targets to multiple ones (Keith et al., 2005). Because nitric oxide synthase and various free radicals are implicated in the initiation and progression of neurodegenerative disorders, more attention is currently being paid to finding multipotent drugs that can surpass the therapeutic effects of selective drugs (Mencher & Wang, 2005).

1.2. Antioxidants

Antioxidants are exogenous (natural or synthetic) or endogenous compounds acting in several ways including removal of O₂, scavenging reactive oxygen species (ROS) or their precursors, inhibiting ROS formation and binding metal ions needed for catalysis of ROS generation. The natural antioxidant system can be classified into two major groups, enzymes and low molecular weight antioxidants (LMWA). The enzymes include SOD, catalase, peroxidase, and other supporting enzymes. The LMWA can be further classified into directly acting antioxidants (e.g., scavengers and chain breaking antioxidants) and indirectly acting antioxidants (e.g., chelating agents). The former
subgroup is extremely important in defence against oxidative stress (OS) and currently contains several hundred compounds. Most of them, including ascorbic and lipoic acids, polyphenols and carotenoids are derived from dietary sources (Shohami et al., 1997).

The cell itself synthesises some biological molecules, such as glutathione and NADPH. The distribution of protective antioxidants in the body has some interesting features. For instance, there is a relatively high concentration of the water soluble antioxidant, vitamin C in the brain. However, vitamin E concentrations in the CNS are not remarkably different from those in other organs. The concentrations of antioxidants also vary within the different regions of the brain itself and the lowest concentration of vitamin E is found in the cerebellum (Vatassery, 1992). It has also been shown that enzymatic antioxidants, such as catalase, are in lower concentrations in the brain than in other tissues.

Melatonin (N-acetyl-5-methoxytryptamine; fig. 1.1) is an indoleamine secreted by the pineal gland and shows structural similarities to serotonin. Melatonin, a biological modulator of many physiological mechanisms (e.g., circadian rhythms and sleep), is highly lipophilic and when administered exogenously, can readily cross the BBB and gain access to neurons and glial cells. There is experimental evidence that melatonin influences aging and age-related processes and disease states. These effects are apparently related to its activity as a free radical scavenger (Beyer et al., 1998).

![Figure 1.1: Melatonin](image)

Electrophysiological experiments have revealed that melatonin inhibits NMDA-induced activity in several brain areas, including the striatum (El-Sherif et al., 2002; León et al., 1998). Melatonin also has anxiolytic actions and anticonvulsant activity against seizures induced by glutamate, NMDA, quinolinate, kainate and pentylenetetrazole in animals (Bijkdaouene et al., 2003; Chung & Han, 2003). Some of these effects have also been shown in humans (Cajochen et al., 2003; Muñoz-Hoyos et al., 1998).
An important consequence of NMDA receptor activation is the production of free radicals and neuronal oxidative damage (Gunasekar et al., 1995) and melatonin has been shown to counteract brain oxidative damage in NMDA and kainate models of excitotoxicity (Reiter, 1998; Giusti et al., 1996). The protective effects of melatonin against brain oxidative stress have also been shown in neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases, where NMDA receptor activation is involved (Acuña-Castroviejo et al., 1995; Reiter, 1998; Brusco et al., 1998; Khaldy et al., 2003). Melatonin also reduces NMDA-dependent nNOS activation in rat cortical cells, cerebellum and striatum (El-Sherif et al., 2002; Yamamoto & Tang, 1998). Conversely, melatonin-deficient rats display increased brain damage after stroke or excitotoxic seizures (Manev et al., 1996). An important part of the brain melatonin action is thus related to inhibition of NMDA-dependent excitation, and this might be correlated to antioxidant activity and/or inhibition of nNOS. Melatonin also controls important neuroendocrine functions by mechanisms involving specific receptors (Acuña-Castroviejo et al., 1995; Dubocovich et al., 2003). However, to date, little is known regarding the exact mechanism of NMDA inhibition by melatonin and the role of melatonin receptors in this effect.

1.3. Enzyme inhibition

The selective inhibition of MAO-B has been shown to have neuroprotective effects in MPTP animal models (Bach et al., 1988). MAO-B inhibition prevents the formation of the toxic MPP+ species by inhibiting the bioactivation of MPTP. There is also evidence that the inhibition of nNOS protects against MPTP mediated neurotoxicity in animals (Cawthon et al., 1981). The potential roles of MAO-B and nNOS in neurodegenerative processes and their selective inhibition are areas of intense investigation. Only a few studies have however considered these two enzymes together. There are also only a few compounds which have been reported both for their MAO-B and nNOS inhibiting properties as well as neuroprotective activity. One of these compounds is 7-nitroindazole (7-NI; fig. 1.2; Mizuno et al., 1987).

![Figure 1.2: 7-Nitroindazole (7-NI)](image-url)
7-NI is a selective inhibitor of nNOS (Berry et al., 1994) and treatment of animals with 7-NI protects against MPTP neurotoxicity (Sket & Pavlin, 1985). These neuroprotective effects were not associated with decreased MPP⁺ production since 7-NI did not inhibit the MAO-B catalysed oxidation of benzylamine by mouse brain mitochondrial preparations. In another study, striatal levels of MPP⁺ in MPTP-treated mice were compared between 7-NI injected and control mice (Westlund et al., 1988). The authors reported that the striatal MPP⁺ levels were unaffected by neuroprotective doses of 7-NI, leading to the conclusion that the neuroprotective effect of 7-NI was mainly due to nNOS inhibition. However, several studies show that planar heterocyclic compounds are inhibitors of MAO-B (Tipton, 1973; Kalaria & Harik, 1987), suggesting that 7-NI, also a planar heterocyclic compound could inhibit MAO-B. This led Castagnoli’s group to investigate the MAO-B inhibiting properties of 7-NI (Glover & Sandler, 1986). The effect of different 7-NI concentrations on the MAO-B catalysed oxidation of MPTP to its metabolite MPDP⁺ was studied in vitro. The results showed that 7-NI had activity as a competitive inhibitor of MAO-B.

7-NI was also found to protect against the MPTP induced depletion of nigrostriatal DA in mice (Lewinsohn et al., 1980). This effect was accompanied by a significant decrease in the striatal levels of MPP⁺ showing that the neuroprotective effect of 7-NI is at least partly mediated through the inhibition of MAO-B. Similar striatal MPP⁺ levels were obtained for both 7-NI together with MPTP and MPTP only treated mice by injecting a higher dose of MPTP in the 7-NI treated mice. In this case, a modest (20 %) protection of DA depletion was observed suggesting that the inhibition of MAO-B may not be the only mechanism mediating the protection against MPTP induced neurotoxicity. According to these results, the neuroprotective effects of 7-NI may be due to MAO-B inhibition, nNOS inhibition or inhibition of both enzymes. The effect of 7-NI and N⁵-nitro-L-arginine, another NOS inhibitor, was also studied on MPTP-induced striatal ATP depletion (Kalaria et al., 1988). The results showed that 7-NI prevented the striatal ATP loss in mice after MPTP administration. However, N⁵-nitro-L-arginine didn’t have any effect on MPTP induced ATP loss, suggesting the importance of MAO-B inhibition rather than NOS inhibition in 7-NI mediated neuroprotection. Another group investigated the effect of 7-NI on 3-nitrotyrosine immunoreactivity in the substantia nigra, which is considered a marker for peroxynitrite mediated neurotoxicity (Konrodi et al., 1989). An increase in 3-nitrotyrosine immunoreactivity was reported in MPTP treated baboons, which was blocked by 7-NI, providing further evidence for the involvement of nNOS
Introduction: Chapter 1

inhibition in protection against MPTP induced neurotoxicity (Fowler et al., 1980). In order to understand the role of 7-NI in neuroprotection better, additional animal studies will have to be done with this compound. However, the low aqueous solubility of 7-NI at pH 7.4 limits its utility in vivo studies and a prodrug approach has been suggested as an avenue to overcome this problem.

1.4. Compounds for synthesis

From the above data it was decided to synthesise a series of polycyclic indole and other polycyclic derivatives (table 1.1). Combinations of the pentacycloundecyl and indole moieties were included to determine the effect it will have on the potency and activity of NOS inhibition and lipid peroxidation.

Table 1.1: Compounds evaluated and synthesised in this study.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Name</th>
<th>Structure</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.0(^2).0(^3).0(^8).0(^9)]undecane-11-one</td>
<td><img src="image1.png" alt="Structure" /></td>
</tr>
<tr>
<td>2</td>
<td>8-[3-(2-aminoethyl)indole]-8,11-oxapentacyclo[5.4.0.0(^2).0(^3).0(^8).0(^9)]undecane</td>
<td><img src="image2.png" alt="Structure" /></td>
</tr>
<tr>
<td>3</td>
<td>3-hydroxy-4-[3-(2-aminoethyl)indole]-azahexacyclo[5.4.1.0(^2).0(^3).0(^8).0(^9).0(^11)]dodecane</td>
<td><img src="image3.png" alt="Structure" /></td>
</tr>
</tbody>
</table>
1.5. Aim of study

The aim of this study was to design and synthesise a series of polycyclic indole derivatives and to evaluate these compounds for neuroprotective activity. A decrease in the production of free radicals due to the inhibition of NOS or direct antioxidant activity, was indicative of neuroprotective potential. This study included:

- Computer modelling to justify the synthesis and biological evaluation of these compounds,
- Synthesis of selected polycyclic indole derivatives and
- In vitro evaluation employing the oxyhemoglobin (NOS inhibition) and TBA (lipid peroxidation) assays.
2. Introduction

Physiological cell death is generally regarded as apoptotic and is mediated by active, intrinsic mechanisms. Pathological (or accidental) cell death is regarded as necrotic, resulting from extrinsic insults to cells (e.g. osmotic, thermal, toxic, traumatic). The process of cellular necrosis involves disruption of membrane structural and functional integrity with rapid influx of $\text{Ca}^{2+}$ and water, resulting in the dissolution of the cell. Cellular necrosis is thus induced by an abrupt environmental perturbation and departure from physiological conditions (Martin et al., 1998).

In this review relevant neurodegenerative aspects and various neurodegenerative strategies, including N-methyl-D-aspartate (NMDA) antagonists, antioxidants and NOS inhibitors will be discussed.

2.1. The lethal triplet

There are three critical mechanisms of neuronal cell death which may act separately or cooperatively to cause neurodegeneration. This lethal triplet of metabolic compromise, excitotoxicity and oxidative stress (Greene and Greenamyre, 1996a; Alexi et al., 1998) causes neuronal cell death that can be classified as being either apoptotic or necrotic (Hughes et al., 1997; Tatton & Chalmers-Redman, 1998). Aspects of each of these three mechanisms are believed to play a role in the neurodegeneration that occurs in Parkinson's disease (fig. 2.1).

![Diagram of the lethal triplet in neuronal cell death](image)

**Figure 2.1:** Lethal triplet in neuronal cell death.
2.1.1. Metabolic compromise

Metabolic compromise of neurons (bioenergetic impairment) can be caused by stroke, asphyxiation, hypoglycemia and certain respiratory poisons. These neurotoxic poisons are mainly mitochondrial poisons and include cyanide, carbon monoxide, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 3-nitropropionic acid (3-NP), malonic acid (MA) and rotenone. As the synthesis of ATP for energy in neurons occurs mainly in the mitochondria via the Krebs-cycle and the electron transport chain, mitochondrial poisoning results in a cytotoxic depletion of ATP.

Both Parkinson's disease (PD) and Huntington's disease (HD) show evidence of deficits in mitochondrial enzymes. Metabolic injuries result in a loss of mitochondrial function leading to a depletion of ATP which causes preferential neurodegeneration in the basal ganglia. Bioenergetic failure causes both a depletion of ATP and deregulates mitochondrial function. Dysfunctioning of mitochondria results in a loss of intracellular calcium buffering capacity and in an increase in the production of damaging oxygen and nitrogen free radicals, leading to oxidative stress. Both these processes can be cytotoxic.

The depletion of ATP causes failure of ATP-dependent ion pumps which results in depolarisation of neurons (Greene and Greenamyre, 1996b). This results in a loss of ionic integrity and an accumulation of intracellular Ca\(^{2+}\). The accumulation of Ca\(^{2+}\) in mitochondria rather than in the cytoplasm may be more critical in determining cell death (Stout et al., 1998). Intracellular Ca\(^{2+}\) further induces mitochondrial strain and free radical generation and increases the neurotoxic processes by activation of Ca\(^{2+}\)-dependent proteases and lipases.

2.1.2. Excitotoxicity

Excitotoxicity is the second aspect of neurotoxicity and occurs due to a dysfunction of excitatory amino acid (EAA) neurotransmission - usually stimulation of glutamate receptors that becomes pathological (Olney et al., 1971). Glutamate is a very important neurotransmitter and controls several functions in the central nervous system (CNS). It is the main excitatory signalling mediator and is implicated in functions such as memory and learning. Nevertheless, glutamate can also produce neurotoxicity and consequently, the glutamate homeostasis must be carefully regulated (Danbolt, 2001).
N-Methyl-D-aspartate (NMDA) receptors are a subtype of glutamate receptors that, upon activation by glutamate can lead to potentially lethal intracellular ionic derangements, in particular, intracellular Na\(^+\) and Ca\(^{2+}\) overload (Dingledine et al., 1999). Excitotoxic neuronal cell death, which tends to occur by necrosis, correlates well with total Ca\(^{2+}\) influx, and removal of extracellular Ca\(^{2+}\) attenuates glutamate-induced neuronal death.

Sustained elevation in intracellular Ca\(^{2+}\) initiates toxic cascades, which ultimately leads to cell death (fig. 2.2). These cascades include activation of catabolic enzymes, such as proteases, phospholipases and endonucleases (Choi, 1995). Elevated concentrations of intracellular Ca\(^{2+}\) can further lead to initiation of protein-kinase and lipid-kinase cascades, impairment of metabolism and generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) responsible for the neuronal damage (Herrling, 1994; Meldrum & Garthwaite, 1990; Sattler & Tymianski, 2000). While many of these events occur early and can result in rapid cell death, others, such as energy compromise and ROS formation, may initiate a more delayed death processes. Most of these Ca\(^{2+}\)-dependent events may be prevalent to both NMDA and AMPA/KA receptor-mediated excitotoxicity.

Ca\(^{2+}\) cytotoxicity follows a complex mechanism and may involve not only Ca\(^{2+}\) overloading but also disruption of intracellular Ca\(^{2+}\) dynamics and mitochondrial ATP synthesis (Castilho et al., 1998). NMDA has been shown to increase not only cytosolic levels of Ca\(^{2+}\) but also mitochondrial Ca\(^{2+}\) concentration (Peng et al., 1998).

An especially important detrimental consequence of Ca\(^{2+}\) overload following excitotoxic glutamate receptor activation is the formation of ROS. Free radical production is linked to elevated [Ca\(^{2+}\)] in several ways: (i) Ca\(^{2+}\)-dependent activation of phospholipase A\(_2\), with liberation of arachidonic acid and further metabolism, leading to free radical production and lipid peroxidation; (ii) activation of nitric oxide synthase (NOS) and the release of nitric oxide (NO), which can then interact with ROS from other sources to generate highly reactive peroxynitrite (Beckman & Koppenol, 1996) and (iii) uncoupling of mitochondrial electron transport, enhancing mitochondrial production of free radicals (Dykens, 1994).
Figure 2.2: Mechanisms contributing to neuronal injury during ischemia-reperfusion. Simplified diagram showing several pathways believed to contribute to excitotoxic neuronal injury in ischemia. mGluR, metabotropic glutamate receptor; NMDA-R, N-methyl-D-aspartate receptor; GluR, AMPA/Kainate type of glutamate receptors; PL, phospholipids; PLA\(_2\), phospholipase A\(_2\); DAG, diacylglycerol; PLC, phospholipase C; PKC, protein kinase C; G, G protein; PIP\(_2\), phosphatidylinositol 4,5-bisphosphate; IP\(_3\), inositol 1,4,5-trisphosphate; NO, nitric oxide; O\(_2^*\), superoxide radical; H\(_2\)O\(_2\), hydrogen peroxide; VSCC, voltage-sensitive Ca\(^{2+}\) channel (Taken from Dugan & Choi, 1999).
Mechanisms in neurodegeneration: Chapter 2

Simplified diagram showing several pathways believed to contribute to excitotoxic neuronal injury in ischemia. mGluR, metabotropic glutamate receptor; NMDA-R, N-methyl-D-aspartate receptor; GluR, AMPA/Kainate type of glutamate receptors; PL, phospholipids; PLA₂, phospholipase A₂; DAG, diacylglycerol; PLC, phospholipase C; PKC, protein kinase C; G, G protein; PIP₂, phosphatidylinositol 4,5-bisphosphate; IP₃, inositol 1,4,5-trisphosphate; NO, nitric oxide; O₂⁻, superoxide radical; H₂O₂, hydrogen peroxide; VSCC, voltage-sensitive Ca²⁺ channel (Taken from Dugan & Choi, 1999).

In cell cultures, ROS production is stimulated by concentrations of NMDA which are not neurotoxic, and in conscious rats, NMDA receptors are responsible for a low baseline production of ROS, suggesting that even "physiological" NMDA receptor activity may trigger production of ROS. However, cell culture studies suggest that substantially greater quantities of mitochondrial ROS are generated when NMDA receptors are sufficiently over-stimulated to produce excitotoxicity. Since AMPA/Kainate receptor activation, possibly in conjunction with the group 1 metabotropic glutamate receptors, may also elicit enhanced mitochondrial ROS production, it is likely that excitotoxicity may be an important trigger for mitochondrial free radical production in ischemia-reperfusion injury. The concept that free radicals are important downstream mediators of excitotoxicity is supported by the fact that treatment with free radical scavengers can attenuate NMDA or AMPA receptor-mediated neuronal death.

2.1.3. Oxidative stress

Oxidative stress on the other hand can be defined as the disruption of the equilibrium between the factors that promote free radical formation and the anti-oxidant defence mechanisms (Olanow, 1993). This process is characterised by the actions of highly reactive free radicals such as the ROS, superoxide anion (\(\cdot O_2^-\)) and hydroxyl radical (\(\cdot OH\)) and the RNS peroxynitrite (ONOO⁻) (Simonian and Coyle, 1996; Cassarino and Bennett, 1999). The oxidising actions of these reactive species destroy membrane lipids, proteins and DNA, and can be detrimental to cells if they accumulate at high levels or if deficits in cellular antioxidant defence systems occur. ROS and RNS are generated under normal cellular functioning, mainly during mitochondrial respiration and are deactivated by endogenous antioxidants and scavengers. Various substances in high
concentration can enhance the production of toxic free radicals, such as intracellular Ca\(^{2+}\), DA and nitric oxide synthase (NOS) (Dyken, 1994; Dawson et al., 1991).

Activation of NOS results in the increased formation of nitric oxide (NO), which can then react with superoxide anion (\(-O_2^-\)) to form peroxynitrite (ONOO\(^-\)). Peroxynitrite can activate the enzyme poly ADP ribosyl synthase (PARS), also called poly ADP ribosyl polymerase (PARP) that goes on to polyribosylate proteins with ADP and which can lead to the depletion of ATP and NAD (Zhang et al., 1994; Szabo et al., 1996). If mitochondrial activity is impaired, the cell cannot replace these energy substrates (NAD and ATP) and the cell subsequently dies. The oxidation of membrane lipids (lipid peroxidation) by free radicals produces a cytotoxic byproduct, 4-hydroxynonenal (HNE), which has recently been identified as a mediator of oxidative stress-induced neuronal cell death (Kruman et al., 1997; Pedersen et al., 1999). Oxidative stress occurs in various neurodegenerative disorders as shown by increases in measures of oxygen and nitrogen free radicals and deficits in antioxidant substances.

The lethal triplet of metabolic compromise, excitotoxicity and oxidative stress may also act cooperatively in causing neuronal cell death. For example, metabolic impairment may elicit secondary excitotoxicity. The depolarisation of neurons and the loss of ionic integrity caused by bioenergetic impairment releases the voltage-dependent block on the NMDA receptor thus activating it and causing secondary excitotoxicity in neurons that possess these receptors (Zeevalk and Nicklas, 1990). The striatum is an example of a glutamaceptive region (receives glutamatergic inputs and has glutamate receptors) and is thus prone to excitotoxic mechanisms. Blockade of excitatory transmission by NMDA receptor antagonists such as MK801 largely prevents striatal damage due to energetic inhibition in vivo, suggesting that toxicity due to metabolic compromise involves an excitotoxic component. However, while metabolic impairment may lead to secondary excitotoxicity, these two neurotoxic events share only partial overlapping mechanisms, as each leads to somewhat different patterns of neuropathology and locomotor dysfunction (Nakao & Brundin, 1997). Metabolic compromise may also cause oxidative stress by inducing the production of free radicals both from the electron transport chain and due to the burden of increased intracellular Ca\(^{2+}\) on mitochondrial function. The reverse interaction may also occur, as oxidative stress may cause metabolic impairment and initiate excitotoxic pathways. For example, oxidative stress can cause lipid peroxidation which yields the byproduct HNE (Morel et al., 1999; Pedersen et al., 1999).
HNE impairs glucose transport which can lead to energetic failure. HNE also renders neurons more sensitive to excitotoxicity as it inhibits Na⁺/K⁺-ATPase activity which is necessary for maintaining neuronal polarisation and therefore the voltage-dependent Mg²⁺ block of the NMDA receptor channel. Also, NO, which promotes the formation of the free radical peroxynitrite, causes mitochondrial depolarisation and depletes ATP (Brorson et al., 1999). Depolarisation of mitochondria impairs the transport of electrons along the mitochondrial matrix during ATP synthesis. This inhibition of metabolic function by NO is partially due to PARS/PARP activation (which causes depletion of ATP by accelerated ATP consumption) via peroxynitrite (Zhang et al., 1994). Excitotoxicity can also contribute to oxidative stress due to the detrimental cascades of events described above. Intrastriatal injection of NMDA ligands results in increases in markers of reactive oxygen species while free radical scavengers and inhibitors of oxidative stress attenuate the neuropathology.

In summary, biological injuries that cause neuronal cell death generally occur through one or more mechanisms of the lethal triplet: metabolic compromise, excitotoxicity and oxidative stress. These events cause a series of intracellular responses which either promote the recovery of the cell or cause cell death. The neuronal cell death that occurs is most likely along an apoptotic and necrotic continuum (Portera-Cailla et al., 1997).

2.2. NMDA receptor in neurodegeneration

The NMDA receptor (fig. 2.3a) is unique among ligand-gated ion channels in that it requires two co-agonists: glutamate and glycine (Kornhuber & Weller, 1997). Normal physiological stimulation of the NMDA receptor has been found to promote survival, maturation and neuronal outgrowth of cultured neurons isolated from the cerebellum, hippocampus or spinal cord (Williams et al., 1991).

The NMDA receptor is complex in that it contains at least five modularly, distinct binding sites:

(i) a site that binds glutamate (or NMDA),
(ii) a regulatory allosteric glycine site,
(iii) a Mg²⁺ binding site, where Mg²⁺ blocks the channel in a voltage-dependent way,
(iv) a PCP or MK-801 binding site and
(v) a site that is modulated by Zn²⁺ binding and the polyamines such as spermine.
Figure 2.3: NMDA receptor model illustrating important binding and modulatory sites.
(a) Glu or NMDA: glutamate or NMDA binding site. Gly, glycine binding site; Zn2+: zinc binding site; NR1, NMDAR subunit 1; NR2, NMDAR subunit 2A; SNO, cysteine sulphydryl group (–SH) reacting with nitric oxide species (NO); X, Mg2+. MK-801, and memantine binding sites within the ion channel pore region. (b) Schematic representation of various domains of the NMDAR subunit. Top, linear sequence; bottom left, proposed 3-D folding; bottom right, proposed tetrameric structure of the classical NMDAR. ATD, amino terminal domain; S1 and S2, agonist binding domains; M1–4, the four transmembrane domains; CTD, carboxyl terminal domain (Taken from Chen & Lipton, 2006).
The NMDA receptor ion channel has a very high Ca\(^{2+}\) conductance and Ca\(^{2+}\) is thought to be the primary mediator of both physiological and toxic properties of the NMDA receptor. In addition to this, the channel can also transport Na\(^{+}\).

The following membrane topology has been proposed for the NMDAR (fig. 2.3b, Wollmuth & Sobolevsky, 2004):

(i) the N-terminal domain contains 380 amino acids that are related to the bacterial periplasmic binding protein sequence designated leucine/isoleucine/valine-binding protein (LIVBP), the Zn\(^{2+}\) binding site, the proton site, and other modulatory sites;
(ii) four transmembrane domains (M1–M4) are present, and the selectivity filter of the channel pore is formed by M2 (a P-loop region);
(iii) the ligand-binding domains are formed by the pre-M1 (S1) and M3-M4 linker region (S2);
(iv) a cytoplasmic C-terminal domain interacts with intracellular proteins (Dingledine et al. 1999); and
(v) the pre-M1 segment, the C-terminal portion of the M3 segment, and the N-terminal region of the M4 segment form the channel outer vestibule (Beck et al. 1999).

In general, NMDAR antagonists can pharmacologically divided into four major groups according to site of action on the receptor-channel complex (Wong and Kemp 1991). Drugs acting at the

(i) NMDA (agonist) recognition site,
(ii) glycine (co-agonist) site,
(iii) channel pore, and
(iv) modulatory sites, such as the redox modulatory site, the proton-sensitive site, the high-affinity Zn\(^{2+}\) site, and the polyamine site.

The degree of NMDAR activation and consequent influx of Ca\(^{2+}\) and Na\(^{+}\) into the cell can be altered by higher levels of agonists and by substances binding to one of the modulatory sites on the receptor. The two modulatory sites that are most relevant are open-channel blocker sites within the ion channel pore and the S-nitrosylation site located towards the N-terminal of the receptor. S-nitrosylation reactions represent transfer of NO to a thiol or sulfhydryl group (–SH) of a critical cysteine residue (Lipton et al. 2002).

Other modulatory sites also exist on the NMDA receptor and may in the future prove to be of therapeutic value. These include binding sites for Zn\(^{2+}\), polyamines, the drug ifenprodil and a pH (i.e. proton) sensitive site (Kemp & McKernan, 2002). Additionally,
Mechanisms in neurodegeneration: Chapter 2

Three pairs of cysteine residues at extracellular domains contribute to the redox sites and can modulate NMDAR function by virtue of their redox sensitivity (Lipton et al. 2002). These redox-sensitive cysteine residues may constitute a unique NO reactive molecular oxygen sensor in the brain, enhancing the degree of down-regulation of NMDA receptor function by S-nitrosylation in the presence of low pO2 levels, and thus dictating the pathological effects of hypoxia that are mediated via the receptor (Chen & Lipton, 2006).

2.3. Neuroprotective strategies

The initiation and duration of a neuroprotective treatment depends on the animal model, the neuroprotective agent and the method of delivery of the agent (Emborg & Kordower, 2000). Prevention of nigral dopaminergic cell loss in PD or animal models of PD requires delivery of neuroprotective agents when there are still cells to be protected. Ideally, neuroprotective substances are administered before the onset of parkinsonian signs. However, we currently lack the tools to preclinically diagnose PD and our best alternative is to start neuroprotective interventions early after the diagnosis of PD (Montgomery et al., 2000a, 2000b).

Several neuroprotective strategies have been suggested and a brief discussion will follow.

2.3.1. Attenuation of excitotoxicity

Attenuation of glutamate-mediated excitotoxicity includes the inhibition of two major classes of glutamate receptors, ionotropic (NMDA, KA and AMPA) and metabotropic (Groups I-III) receptors, coupled to intracellular second messengers (Pitkanen et al., 2005). Many reports have targeted the NMDA receptor (table 2.1), where MK-801, phencyclidine (PCP) and ketamine showed strong psychomimetic effects. The occurrences of adverse effects were diminished in later generations of NMDA receptor antagonists such as NPS 1506 and NPS 846. To date, magnesium, HU-211 (dexanabinol), memantine and Cp-101,606 have generated clinical interest because of improved functional and histological outcomes (Morales et al., 2005). In addition to antagonism of excitatory amino acid (EAA) receptor function, modulation of EAA receptor activity might also be accomplished by inhibition of EAA release. Examples include the compound riluzole which is currently in Phase III clinical trials. Despite promising preclinical documentation, all glutamate blockers evaluated to date, have shown to be ineffective in Phase III clinical trials (Marklund et al., 2004; table 2.1).
### Table 2.1: Targets of neuroprotection in traumatic brain injury (Taken from Pitkanen et al., 2005).

<table>
<thead>
<tr>
<th>Pharmacological target</th>
<th>Examples of compounds</th>
</tr>
</thead>
</table>
| EAA 
modulation                    | Mg²⁺, CPI 101-606⁻, MK-801⁻, HU-211⁻, Memantine⁹⁰⁶ |
| NMDA³⁻/KA¹⁺                      | RPR117824⁻¹⁰, YM872¹¹, NBQX¹² |
| Metabotropic                      | MCPP¹³, AIDA¹⁴, CPCCOEt¹⁵, LY-367385¹⁷, MPEP¹⁷, DCG-IV¹⁸, LY354740¹⁹ |
| EAA release inhibition           | BW1003C87²⁵, 619C89²¹, Riluzole                           |
| ROS⁵ scavenging                   | PBN²², S-PBN²³, Vitamin E, L-NAME²⁴, CDPC²⁵, PEG-SOD²⁶ |
| Calcium-mediated damage          | LOE908²⁷, SNX-111²⁸                                      |
| Modulators of inflammation        | IA²⁹, Ibuprofen, HU-211, CP-0127³⁰                      |
| Miscellaneous                     | GPI 6150³¹, CsA³², CCPA³³, Lactate                      |
| Neurotoxic factors                | NGF³⁴, GDNF³⁵, BDNF³⁶                                     |
| Inhibitors of apoptosis           | Z-VAD-fmk³⁷, Z-DEVD-fmk³⁸                                |
| Endocrinology                     | TRH³⁹, analogs, IGF-¹⁰, DHEAS⁴¹, progesterone            |

¹EAA: excitatory amino acid; ²NMDA: N-methyl-D-aspartate; ³AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; ⁴KA: kainate receptors 1 and 2; ⁵ROS: reactive oxygen species; ⁶CPI 101-606: (1S,2S)-1-(4-hydroxyphenyl)-2-4-hydroxy-4-phenylpiperidine-1-propanol; ⁷MK-801: dizocilpine maleate; ⁸HU-211: (+)-(3S,4S)-7-hydroxy-1,6 tetrahydro-cannabinol 1,1-dimethylheptyl; ⁹Memantine: 3,5-dimethyl-L-adamantanamine; ¹⁰RPR117824: 9-carboxymethyl-imidazo-[1-2a]indenol[1-2e]; ¹¹YM872: zonampanel monohydrate; ¹²NBQX: 6-nitro-7-sulfamoylbenzof (F) quinoxaline-2,3-dione; ¹³MCPG: (S)-α-4-carboxyphenylglycine; ¹⁴AIDA: (RS)-L-aminoidan-1,5-dicarboxylic acid; ¹⁵CPCCOEt: 1-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylic acid ethyl ester; ¹⁶(S)-(+)-α-amino-4-carboxy-2-methylbezenecarboxylic acid; ¹⁷MPEP: 2-methyl-6-(phenylethynyl)-pyridine; ¹⁸DCG-IV: 2, (2,3)-dicarboxycyclopropylglycin; ¹⁹LY354740: (1S,2S,5R,6S)-(+)·2·aminobicyclo[3.1.0]hexane·2,6-dicarboxylic acid; ²⁰BW1003C87: 5·(2,3,5-trichlorophenyl) pyrimidine 2,4-diamine ethane sulfonate; ²¹619C89: [4-amino-2·(4-methyl-1-piperazinyl)·2·(3,5-trichlorophenyl)pyrimidine mesylate monohydrate]; ²²PBN: α-phenyl-N-tet butyl-nitrom; ²³S-PBN: sodium 2-sulfophenyl-N-tet butyl nitrom; ²⁴L-NAME: nitro-L-arginine methyl ester; ²⁵CDPC: cytidine 5′-diphosphocholine; ²⁶PEG-SOD: polyethylene glycol-conjugated superoxide dismutase; ²⁷LOE908: (R,S)-(3,4-dihydro-6,7-dimethoxy-isoquinoline-1-yl)-2-phenyl-N,N-d(2·(2,3,4-trimethoxyphenyl)ethyl)-acetamide; ²⁸SNX-111: Ziconotide; ²⁹IA29: anti-iCAM-1 monoclonal antibody; ³⁰CP-0127: Bradycol or deltalint, bissuccimidohexane (L-Cys-S)-; ³¹GPI 6150: (1,1b-dihydro-2H)bezopyran[4,3,d]isoquinolin-3-one; ³²CsA: cyclosporin A; ³³CCPA: 2-chloro-N(6)-cyclopropyladenosine; ³⁴NGF: nerve growth factor; ³⁵GDNF: gial cell-derived neurotrophic factor; ³⁶BDNF: brain-derived neurotrophic factor; ³⁷Z-VAD-fmk: acetyl-Tyr-Val-Ala-Asp-chloromethyl-ketone; ³⁸Z-DEVD-fmk: N-benzoyloxy-carbonyl-Asp-Glu-Val-Asp-fluoromethyl ketone; ³⁹TRH: thyrotropin-releasing hormone; ⁴⁰IGF-1: insulin-like growth factor-1; ⁴¹DHEAS: dehydroepiandrosterone sulfate.

#### 2.3.2. Calcium channel blockage and calpain inhibition

Several Ca²⁺ blockers such as (S)-emopamil, LOE 908, S100B, BMS-204352 and SNX-111 have been shown to attenuate neurological motor and cognitive deficits following experimental traumatic brain injury (Morales et al., 2005). Much clinical interest, to date,
has focused on the Ca\textsuperscript{2+}-channel blocker nimodipine, but considerable uncertainty remains as to its efficacy (Langham et al., 2003).

Downstream inhibition of calpains (Ca\textsuperscript{2+}-dependent proteases) might also be of therapeutic value. The calpain inhibitor AK295 has shown to reduce both motor and cognitive deficits, while the calpain inhibitor MDL-28170 reduced the damage of brainstem fiber tracts. However, its efficacy as calpain inhibitors need to be further investigated (Pitkänen et al., 2005).

2.3.3. Reactive oxygen and nitrogen scavengers

Tirilazad mesylate and its related pyrrolopyrimidines, including U-101033E, showed promising effects in a series of traumatic brain injury (TBI) studies, but Phase III clinical trials have failed to show a positive outcome (Roberts et al., 2000). Inhibition of lipid peroxidation and/or attenuation of hydroxyl radicals are of clinical interest and further evaluation are ongoing.

Cytidine 5'-diphosphocholine (CDPC), or citicoline, compounds that attenuate the activation of phospholipase A\textsubscript{2}, have shown to be neuroprotective and possess neurobehavioral efficacy (Dempsey & Raghavendra, 2003). CDPC improved the motor and cognitive outcome, implying a potential role for CDPC in the treatment of human TBI.

2.3.4. Superoxide scavenging

Administration of the antioxidant enzyme superoxide dismutase (SOD) conjugated to enhance blood-brain barrier penetration (PEG-SOD, pegogortein) improved survival and neurological recovery, attenuated cerebral edema and decreased hippocampal cell loss across TBI models. PEG-SOD failed in the randomised, Phase III multicenter trial and the reason for this failure are probably multifactorial but might be related to the inclusion of many severely brain-injured patients (Young et al., 1996).

2.3.5. Pharmacological inhibition of caspases and pro-apoptotic cascades

Another strategy to prevent acute cell death after TBI might be to inhibit caspases, the enzymes involved in the process leading to apoptosis. Several caspase inhibitors have been successfully evaluated in TBI models including ketones such as the pan-caspase inhibitor z-VAD-fmk, the caspase-1 specific inhibitor acetyl-Tyr-Val-Ala-Asp-chloromethyl ketone and the caspase-3-specific z-DEVD-fmk (Raghupathi, 2004). However, the role
Mechanisms in neurodegeneration: Chapter 2

of anti-apoptotic compounds in TBI is controversial and more preclinical research is necessary to evaluate their clinical potential.

Several studies have demonstrated that exogenously administered progesterone or its metabolite alphapregnanolone reduced post-traumatic increase in cerebral edema, improved cognitive performance and functional deficits and reduced lesion volume and apoptotic cell death (Djebarli et al., 2005).

2.4. Enzyme inhibition

2.4.1. Nitric oxide synthase

There is evidence that not only reactive oxygen species but also nitric oxide (NO), a free radical, may play a role in oxidative damage in PD (Gerlach et al., 1999). Nitric oxide (NO) has a broad range of biological activities and acts as cell messenger with important regulatory functions in the nervous, immune and cardiovascular systems (Moncada et al., 1991). Overproduction of NO however, plays a role in a variety of disorders such as septic shock, pain, ischemia and several neurodegenerative diseases (Dawson & Dawson et al., 1996).

NO is formed via the nitric oxide synthase (NOS) catalysed conversion of L-arginine (27) to L-citrulline (29; Kerwin et al., 1995), a process that leads to the formation of free radical nitric oxide (NO).

\[
\begin{align*}
\text{H}_2\text{N} & \quad \text{NH}_2 \\
\text{N} & \quad \text{N} \\
& \quad \text{COO}^- \\
\text{H}_3\text{N} & \quad \text{COO}^- \\
\text{27} & \\
\end{align*}
\]

\[
\begin{align*}
\text{H}_2\text{N} & \quad \text{NO} \quad \text{NH} \\
\text{N} & \quad \text{N} \\
& \quad \text{COO}^- \\
\text{H}_3\text{N} & \quad \text{COO}^- \\
\text{28} & \\
\end{align*}
\]

\[
\begin{align*}
\text{H}_2\text{N} & \quad \text{NO} \\
\text{N} & \quad \text{N} \\
& \quad \text{COO}^- \\
\text{H}_3\text{N} & \quad \text{COO}^- \\
\text{29} & \\
\end{align*}
\]

\[
\begin{align*}
\text{NADPH} + \text{O}_2 & \quad \rightarrow \\
\text{H}_2\text{YNH}_2 & \quad \text{H}_2\text{YNoH} \\
\text{27} & \quad \text{28} \\
\end{align*}
\]

\[
\begin{align*}
\text{NADPH} + \text{O}_2 & \quad \rightarrow \\
\text{H}_2\text{YNH}_2 & \quad \text{H}_2\text{YN} \quad \text{NO} \\
\text{27} & \quad \text{28} \quad \text{30} \\
\end{align*}
\]

Scheme 2.1. NOS catalysed conversion of L-arginine (27) to L-citrulline (29) and NO (30).

The development of neuroprotective agents is orientated toward the synthesis of novel structures that interfere with some step of the complex chemical signaling system involving NOS, including the inhibition of the enzyme itself.
2.4.2. Structure

Nitric oxide synthases (NOS), the enzymes responsible for synthesis of NO consists of homodimers whose monomers are two fused enzymes themselves: a cytochrome reductase and a cytochrome that requires three co-substrates (L-arginine, NADPH and O₂) and five cofactors or prosthetic groups (FAD, FMN, calmodulin, tetrahydrobiopterin and heme (fig. 2.4).

This enzyme is comprised of an N-terminal oxidase domain with binding sites for L-arginine and tetrahydrobioprotein (H₄B) and a C-terminal reductase domain with binding sites for FMN, FAD, and NADPH (fig. 2.5). The domains are connected by a Ca²⁺/calmodulin binding region that allows electron transport through the enzyme (Marletta, 1993; Roman et al., 2002). In its functional state, NOS is a dimer in which electrons from one subunit of the oxygenase domain accepts electrons from FMN of the reductase domain of the other subunit (Siddhanta et al., 1998). This unique enzyme catalyses a two-step monooxygenase reaction, converting L-arginine to N⁴-hydroxyl-L-arginine, as an intermediate and then to L-citrulline and NO (Stuehr et al., 1991; Rosen et al., 2002).

Figure 2.4: A manually constructed docking model showing possible interactions between CaM complexed with a helical peptide from human eNOS (1N1W) and the rat nNOS reductase domain (1TLL). The C-terminal helix is hidden behind the FMN binding domain. Cofactors FMN, FAD, and NADPH are shown as ball-and-sticks, while Ca²⁺ ions in CaM are represented as gold spheres (Taken form Li & Poulos, 2005).
Neuronal nitric oxide synthase also generates superoxide ($O_2^-$) and hydrogen peroxide ($H_2O_2$) during enzymatic cycling (Pou et al., 1992). There are a number of control mechanisms that regulate nNOS production of NO, $O_2^-$, and $H_2O_2$. For instance, $H_4B$ appears to play a critical role in the NOS oxidation of L-arginine to NO and L-citrulline (Presta et al., 1998). Similarly, this pterin, in the absence of L-arginine, promotes direct generation of $H_2O_2$ at the expense of $O_2^-$ (Rosen et al., 2002). Finally, L-arginine, by binding to nNOS, shifts electron transport away from $O_2$, increasing NO production at the expense of $O_2^-$ (Pou et al., 1999), since NO, $O_2^-$, and $H_2O_2$ initiate different cell signaling pathways (Wolin, 2000; Droge, 2002), such as lipid peroxidation (fig. 2.2).

![Domain structure of human nNOS, eNOS and iNOS.](image)

**Figure 2.5:** Domain structure of human nNOS, eNOS and iNOS.

Oxygenase, reductase and PDZ domains are denoted by solid boxes and the amino acid residue number at the start/end of each domain is shown. The cysteine residue which ligates the heme and the CaM-binding site is indicated for each isoform, myristoylation (Myr) and palmitoylation (Palm) sites on eNOS are shown, as is the location of the zinc-ligating cysteines (Zn in grey). The auto inhibitory loop within the FMN regions of nNOS and eNOS are also shown and grey bars indicate the dimer interface in the oxygenase domain (Taken from Alderton et al., 2001).
2.4.3. NOS isoforms

Several distinct NOS isoforms are expressed from three distinct genes. These include two constitutive Ca$^{2+}$/CaM-dependent forms of NOS: neuronal nitric oxide (nNOS) whose activity was first identified in neurons, and endothelial nitric oxide synthase (eNOS) first identified in endothelial cells. These two isoforms are physiologically activated by steroid hormones or neurotransmitters such as NO, DA, glutamate and glycine that increase the intracellular calcium concentrations. In contrast, the inducible form of nitric oxide synthase, iNOS, is Ca$^{2+}$ independent and is expressed in a broad range of cell types. This form of NOS is induced after stimulation with cytokines and exposure to microbial products. After permanent activation, it continuously produces high concentrations NO.

Since these isoforms possess a distinct cellular localisation and are differentially regulated, they represent specific targets for potential therapeutical approaches (table 2.2).

Table 2.2: Postulated roles for NO synthesised by three NOS isoforms (Knowles, 1996).

<table>
<thead>
<tr>
<th>nNOS</th>
<th>eNOS</th>
<th>iNOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central nervous system</td>
<td>Cardiovascular system</td>
<td>Nonspecific immunity</td>
</tr>
<tr>
<td>Neurotransmitter/neuromodulator</td>
<td>Relaxation of vascular smooth muscle; regulation of</td>
<td>Resistance to infection by</td>
</tr>
<tr>
<td></td>
<td>• tissue conductance</td>
<td>• Protozoa</td>
</tr>
<tr>
<td></td>
<td>• blood flow</td>
<td>• Fungi</td>
</tr>
<tr>
<td></td>
<td>• blood pressure</td>
<td>• Bacteria</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Viruses</td>
</tr>
</tbody>
</table>

Responses to glutamate

- Peripheral nitrergic nerve neurotransmitter
  - GI Tract
  - Penile erection
  - Sphincter relaxation
  - Blood flow

Pathological roles

- Ischaemic brain damage
- Hyperalgesia
- Epilepsy
- Parkinson's disease

Blood flow of tissue conductance blood flow

Inflammatory/autoimmune diseases

- Acute inflammation
- Ulcerative colitis
- Asthma
- Transplant rejection
- Arthritis, prosthetic joint failure
- Multiple sclerosis?
- Dementias (Alzheimer's, Lewy body, viral)

Tumours

- Promotion of vascularisation, growth and metastasis
2.4.4. NOS Inhibitors

Since the development of selective inhibitors only a few specific isoforms are of considerable interest, both for therapeutic purposes and for their use as specific pharmacological tools. For example, NO of neuronal origin is involved in pain transmission (Moore et al., 1991; Moore et al., 1993) and thus constitutes a potential target for antinociceptive drugs. However, such a drug needs to be selective for nNOS, i.e., leaving the eNOS unaffected, to avoid hypotensive side effects. Though there is a low homology between the three human NOS primary sequences (approximately 50%), the active site of the enzymes seems to be relatively conserved (Li et al., 1999), presumably explaining the difficulty to obtain selective inhibitors.

Several nNOS inhibitors have been developed over the last decade but only few present both potency and a clear selectivity toward this isoform. The first inhibitors developed belong to the L-arginine analogue family (Dwyer et al., 1991) and are mostly not selective for the neuronal isoform. Another series of inhibitors is constituted by heterocycles such as substituted indazole and imidazole. It has been reported that 1-(2-trifluoromethylphenyl) imidazole (TRIM) has a relative selectivity for nNOS in comparison to eNOS but its potency is rather weak (IC50=30 mM for nNOS) (Handy et al., 1996). The nitroindazole family (with 7-nitroindazole as the lead compound) are more potent nNOS inhibitors but their selectivity over the other isoforms remain low, at least in vitro (Moore et al., 1991; Babbedge et al., 1993). It has also been reported that melatonin (fig. 2.6), a compound secreted by the pineal gland, can inhibit the nNOS activity in rat striatum in a dose-dependent manner (León et al., 1998).

![Melatonin structure](image)

**Figure 2.6:** Melatonin

It is important to note that while some compounds are apparently selective for one or other isoform in vivo, they may show no real selectivity at the enzyme level. For example, 7-nitroindazole (7-NI) has been shown to be a selective nNOS inhibitor in vivo but when studied at the isolated enzyme level it is in fact equally effective as an inhibitor of all three NOS enzymes.
2.4.4.1. Endogenous inhibitors

L-NMMA (N\(^\ominus\)-monomethyl-L-arginine) and asymmetric dimethylarginine (ADMA) are synthesised by methylation of arginine residues in proteins (Leiper and Vallance, 1999) and act as endogenous inhibitors of NOS (fig. 2.7, table 2.3). Methylarginines are released into the cell cytosol on degradation of the protein where they can act as competitive inhibitors of all three isoforms of NOS.

![L-NMMA and ADMA structures](image)

**Figure 2.7:** Structures of naturally occurring NOS inhibitors.

An alternative therapeutic approach to regulate NO synthesis could thus be by the manipulation of endogenous NOS inhibitors. These naturally occurring NOS inhibitors are metabolised to citrulline by the action of the enzyme dimethylarginine dimethylaminohydrolase (DDAH; Vallance & Leiper, 2002; Vallance, 2003). Inhibition of this enzyme leads to accumulation of methylarginines inhibiting NO production. Two isoforms of DDAH have been identified (Leiper et al., 1999); one of which is expressed mainly in nerve tissue and another which is widely expressed in vascular and other tissues. This differential tissue distribution of DDAH could potentially be used as a method to manipulate NO overproduction by regulating endogenous NOS inhibitors in a specific cell type or tissue. An advantage of this would be that these NOS inhibitors would only accumulate to levels that partially inhibit NOS and the detrimental effects of complete NOS inhibition could probably be avoided.

2.4.4.2. Substrate analogues for NOS enzymes

The first described inhibitors of NOS were analogues of the substrate L-arginine. These compounds are thought to bind competitively at the arginine-binding site, a fact that has been confirmed for aminoguanidine (fig. 2.8), S-ethylisothiourea and thiocitrulline (Alderton et al., 2001). For many of the arginine-site NOS inhibitors there are however other mechanisms involved in their mode of action that cannot be explained by simple competition with L-arginine.
Mechanisms in neurodegeneration: Chapter 2

There is a whole series of substrate analogues and these are shown in fig. 2.8 and table 2.3 and include aminoguanidine, L-NMMA, 1400W, (N-[3-(aminoethyl)benzyl]acetamidine), L-NIL (N⁶-iminoethyl-L-lysine), L-NIO (N⁶-iminoethyl-L-ornithine), GW273629 (S-[2-[(1-iminoethyl)-amino]ethyl]-4,4-dioxo-L-cysteine), GW274150 (S-[2-[(1-iminoethyl)-amino]ethyl]-L-homocysteine). Aminoguanidine has been shown to be beneficial in rodent models of stroke but its selectivity for NOS should be taken in context with its inhibitory effects on advanced glycosylation end-product formation, diamine oxidase and polyamine metabolism.

![Chemical structures](image)

**Figure 2.8:** Selected substrate analogues as NOS inhibitors.
The first highly selective iNOS inhibitors described were the bis-isothioureas (e.g. PBTIU or S,S-1,3-phenylene-bis(1,2-ethanediyl)bis-isothiourea (fig. 2.9). Although these compounds have some selectivity for iNOS over eNOS, their development as potential drugs was limited due to their toxic effects, that includes action at Na⁺/K⁺ ATPase. Binding studies with more bulky ligands led to the construction of a set of criteria by which an isoform-selective inhibitor could be developed. These are as follows:

- A structural scaffold that provides a guanidino, amidino or ureido group that donates hydrogen bonds to the glutamate residue in the NOS active site is required. There should also be a small hydrophobic group, such as an alkyl or thiienyl group, to provide further non-polar interactions with the protein opposite to the glutamate residue.
- An isoform-selectivity-conferring functional group bearing hydrogen-bonding capability that can reach into the substrate-access channel remote from the active site. Such a group could take advantage of the amino acid differences in this channel between isoforms.
- A linker between the scaffold and the functional group of appropriate length and flexibility to reach isoform-specific regions.

In patients with septic shock the nonselective NOS inhibitor, L-NMMA, restored blood pressure and seemed to improve haemodynamics (Petros et al., 1991, 1994). However, one of the largest clinical trials involving the use of NOS inhibitors, showed adverse effects. Low doses of these inhibitors may be beneficial, however larger doses resulted in a negative outcome (Grover et al., 1998, 1999a,b). This phase III clinical trial, using L-NMMA as a treatment for patients with sepsis, had to be terminated early due to increased mortality as a result of an L-NMMA-induced fall in cardiac index in a number of patients (Grover et al., 1998, 1999a,b). This was despite improving peripheral vascular tone. The mechanisms involved are unknown but are probably due to direct effects on cardiac tissue.
Mechanisms in neurodegeneration: Chapter 2

Figure 2.9: Structures, co-factor inhibitors and isothioureas as NOS inhibitors.

In contrast, L-NMMA has been used to reduce UVB-induced skin inflammation, to treat headache and to block excess NO exhalation in asthma (Ashina et al., 1999; Warren, 1994). However, Suda et al. (2002) found that prolonged treatment with L-NAME (N\textsuperscript{G}-nitro-L-arginine methyl ester) in eNOS knockout mice enhanced atherosclerosis suggesting that some NOS inhibitors have other harmful effects that are independent of their actions on NOS.
Table 2.3: NOS inhibitors: selectivity, potency and potential clinical applications

<table>
<thead>
<tr>
<th>Compound</th>
<th>Clinical/model uses</th>
<th>Selectivity</th>
<th>IC_{50} (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOS inhibitors: selectivity, potency and potential clinical applications</td>
<td></td>
<td>iNOS vs. eNOS</td>
<td>nNOS vs. eNOS</td>
</tr>
<tr>
<td>Compound</td>
<td>Clinical/model uses</td>
<td>Selectivity</td>
<td>IC_{50} (μM)</td>
</tr>
<tr>
<td>L-NMMA</td>
<td>Unsuitable for sepsis, used for headache, reduces exhaled NO in asthmatics and UVB induced skin inflammation</td>
<td>0.5</td>
<td>0.7</td>
</tr>
<tr>
<td>L-NNA</td>
<td>Data unavailable</td>
<td>0.11</td>
<td>0.09</td>
</tr>
<tr>
<td>1400W</td>
<td>Not suitable for use in humans due to toxicity</td>
<td>&gt;4000</td>
<td>32</td>
</tr>
<tr>
<td>L-NIL</td>
<td>L-NIL prodrug SC51 decreases exhaled NO in asthmatics</td>
<td>9</td>
<td>23</td>
</tr>
<tr>
<td>Vinyl L-NIO</td>
<td>Possible use to define the therapeutic potential for nNOS manipulation</td>
<td>5</td>
<td>0.002</td>
</tr>
<tr>
<td>7-NI</td>
<td>Attenuates lung injury in animal models and is involved in neuroprotection*</td>
<td>1.2</td>
<td>0.9</td>
</tr>
<tr>
<td>ARL 17477</td>
<td>Protective in animal model of cerebral ischemia</td>
<td>5</td>
<td>0.2</td>
</tr>
<tr>
<td>AR-C102222</td>
<td>Effective reduction of inflammation in models</td>
<td>&gt;1000</td>
<td>50</td>
</tr>
<tr>
<td>GW273629</td>
<td>Reduces experimental postoperative ileus, beneficial in models of gastric damage</td>
<td>&gt;125</td>
<td>&gt;1.6</td>
</tr>
<tr>
<td>Compound</td>
<td>Description</td>
<td>GW274150</td>
<td>1000</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------</td>
<td>------</td>
</tr>
<tr>
<td>Aminoguanidine</td>
<td>Reduces experimental postoperative ileus, beneficial in models of gastric damage</td>
<td>78</td>
<td>1000</td>
</tr>
<tr>
<td>PBTIU</td>
<td>Use limited in humans due to toxic effects involving Na^+K^+ ATPase</td>
<td>11</td>
<td>5.5</td>
</tr>
<tr>
<td>FR038251</td>
<td>Different potencies and selectivities for NOS isoforms; possible iNOS inhibitor unknown effects in humans</td>
<td>190</td>
<td>N/A</td>
</tr>
<tr>
<td>FR038470</td>
<td>Different potencies and selectivities for NOS isoforms; possible iNOS inhibitor unknown effects in humans</td>
<td>8</td>
<td>13</td>
</tr>
<tr>
<td>FR191863</td>
<td>Not available</td>
<td>38</td>
<td>1.7</td>
</tr>
</tbody>
</table>


The novel and highly selective iNOS inhibitor 1400W has been shown to reduce formation of oedema, neutrophil infiltration and macroscopic damage in experimentally induced acute colitis in the rat and supports the notion that selective iNOS inhibitors may be used in colitis treatment (Kankuri et al., 2001). In addition, this compound has been shown to inhibit growth of solid cultured cancer cells (Thomsen et al., 1997). However, the clinical use of 1400W in humans is doubtful due to its toxicity at high doses (Garvey et al., 1997; Kankuri et al., 2001; Thomsen et al., 1997). Other compounds in this series include GW273629 and GW274150 and have been shown to reduce experimental postoperative ileus and may be beneficial in models of gastrointestinal damage.

Astra Zeneca developed a spiroquinazolone derivative denoted AR-C102222 which represents an alternative chemical approach for NOS inhibition. This compound has an IC50 of 0.04 μM, and is reported to be highly selective for iNOS. In in vivo studies, it was found to be effective in reducing inflammation in the standard carrageenan paw oedema model and decreased adjuvant-induced arthritis in rats (Beaton et al., 2001).

Structural modifications to one of the guanidine nitrogens of L-arginine led to the development of L-NNA (N\textsuperscript{\texttext{-}}-nitro-L-arginine), L-NAME and aminoguanidine, all of which are competitive inhibitors of NOS. Two recently developed compounds, based on aminoguanidine, PL-AG (pyridoxal aminoguanidine, fig. 2.10) and 8Q (8-quinolinecarboxylic acid hydrazide) have been shown by Pekiner et al. (2002) to selectively inhibit basal but not agonist stimulated NO production in the rat aorta.

L-NIO has been shown to be more selective for nNOS than iNOS or eNOS (table 2.3, Babu & Griffith, 1998a,b) and recent work by Hansel et al., (2003) indicated that L-NIL (Fig. 2.8, table 2.3) inhibited iNOS activity. Furthermore, in a clinical trial using normal and asthmatic individuals it was shown that the prodrug of L-NIL, SC51 inhibits exhaled NO. This drug was well-tolerated and had no adverse effects on heart rate, blood pressure or forced expiratory volume. Whether such compounds or related versions will be of use therapeutically remains to be investigated.

Reducing harmful over-production of NO has vast therapeutic potential and inhibition of iNOS in particular has great use as an anti-inflammatory target in many diseases. Inhibition of nNOS has potential in CNS disorders involving neurodegeneration, neurotoxicity and pain (Low, 2005). Inhibition of NOS isoforms could however have detrimental consequences in addition to their beneficial effects. For example, if nNOS is
inhibited in the gastrointestinal and genitourinary systems it can cause spasm of the sphincters.

If iNOS is not selectively inhibited it could create a situation where under certain circumstances wound healing was inhibited and the risk of infection increased. In addition to permit prolonged use of NOS inhibitors, it is necessary to use isoform specific inhibitors with a greater degree of selectivity to eliminate the potential risk of unwanted inhibition of eNOS which could have the consequences of hypertension, increased activation of platelets and white blood cells and atherogenesis. For example, with isoform specific inhibitors, it might be preferable to inhibit NOS in specific cells or tissues. Birrell et al. (2003) have shown in models of allergic inflammation, and using 1400W to inhibit iNOS, that constitutive rather than inducible NOS isoforms are important and this has implications for the treatment of asthma where it might not be appropriate to use iNOS inhibitors as therapy.

In cancer (e.g. gliomas), another medicinal field of potential use is based upon the hypothesis that suppression of tumoural NOS has more of a therapeutic effect than an oncogenic effect. Some preliminary rodent studies using L-NAME in the C6 striatal implantation model showed inhibition of tumour growth and increased tumour necrosis (Swaroop et al., 2000) and studies using iNOS knockout C6 cells suggested that iNOS was required for tumourogenicity (Yamaguchi et al., 1999). Although both pharmacological and genetic engineering studies of various nonglial malignant cell lines in vivo have also suggested that NOS is important for tumourogenicity, other studies have shown that enhancement of iNOS activity leads to decreased tumourogenicity (Shinoda & Whittle, 2001). Further work on the biochemical and toxicological mechanisms of NO in gliomas will be required to clarify its potential for therapy.
Figure 2.10: NOS inhibitors containing guanidine moieties.
2.5. Polycyclic amines and indole derivatives

Since the description of the antiviral properties of the adamantane amine, 1-amino-adamantane or amantadine (Davies et al., 1964), significant interest into the chemistry of polycyclic amines has been shown. The pharmacological properties of the adamantane amine derivatives are well known and led to further investigation into the polycyclic cage amine derivatives.

Biological activity described for a class of polycyclic amine derivatives, the pentacycloundecylamines (fig. 2.11), suggests possible neuroprotective abilities for these compounds through modulation of voltage activated sodium, potassium and Ca\(^{2+}\) channels, as well as interaction with NMDA receptor operated channels. They show structural similarities to known NMDA antagonists, and their peripheral L-type calcium channel activities have also been described (Geldenhuys et al., 2003a Van der Schyf et al., 1986; Van der Walt et al., 1988).

NMDA antagonists like amantadine and memantine have been clinically approved for the treatment of PD and AD (Lipton & Chen, 2004). In addition, memantine did not substantially affect normal synaptic activity and still prevented excessive NMDA receptor activation. Unlike other NMDA receptor antagonists, side effects are averted with memantine because of the preservation of physiological neurotransmission (Lipton & Chen, 2004).

Structural similarities and comparable activities between the pentacyclic cage compounds and adamantanamines indicate therapeutic potential for the former compounds (Oliver et al., 1991a,b,c). These authors suggested that polycyclic amines may have potential as a new class of anti-parkinsonian agents due to their anticataleptic and anticholinergic activities. L-Type calcium channel antagonism has also been described for pentacycloundecylamines, in particular for the prototypical compound 8-benzyl-8,11-oxapentacyclo[5.4.0.0\(^2,6\).0\(^3,10\).0\(^5,9\)]undecane (NGP1-01, fig. 2.11a, R=NHCH\(_2\)Ph) which was extensively studied in this regard (Malan et al., 2000; Van der Schyf et al., 1986).
a) Pentacycloundecylamine derivative  b) Amantadine  c) Memantine

**Figure 2.11:** Structural similarities between the pentacycloundecane derivatives with amantadine and memantine.

The structural resemblance between the polycyclic cage structure of memantine and NGP1-01 prompted the evaluation of these compounds and their derivatives for possible neuroprotective activity (Geldenhuys et al., 2003b). Putative protective activity was hypothesised to be initiated by a dual mechanism of action including attenuation of NMDA receptor activity and direct blocking of L-type Ca\(^{2+}\) channels, thereby preventing excessive influx of Ca\(^{2+}\) into neuronal cells.

Another benefit of the pentacycloundecylamines is their ability to enter the CNS. For drugs to exert meaningful effects in the CNS they have to cross the BBB and it was found that the pentacycloundecylamines penetrate the CNS in sufficient concentration to exert pharmacological effects (Zah et al., 2003). It was proposed that the main mode of entry into the CNS was by means of passive diffusion across the BBB, due to the inherent hydrophobic nature of the polycyclic structure.

The polycyclic cage thus appears to be a useful scaffold to explore in order to design potential pharmacologically active compounds in the field of neurodegeneration.

### 2.6. Conclusion

Multiple synergistic pathways have been suggested to play crucial roles in the cell death cascade. Therefore, it would be an effective therapeutic strategy to employ a combination of compounds to affect multiple target sites in the cell-destruction pathway. Drugs such as budipine, an NMDA receptor antagonist; the dihydropyridine type of Ca\(^{2+}\) channel antagonists; N-nitro-L-arginine, an NO inhibitor; and iron chelators represent candidates for Parkinson's disease treatment. Perhaps the most effective mode of cell-protective therapy would be a combination of these compounds as opposed to monotherapy.
From the literature it is clear that 7-nitroindazole and melatonin have positive and promising effects in the treatment and prevention of neurodegenerative disorders. Melatonin treatment however, may be problematic due to its various physiological roles and multiple undesirable side effects. Experimental evidence also shows that melatonin influences aging and age-related processes and disease states. These effects are apparently related to its effectiveness as a free radical scavenger (Beyer et al., 1998). Its possible mechanism of action include removal of $O_2$, scavenging of reactive oxygen species or their precursors, inhibiting ROS formation and binding metal ions needed for catalysis of ROS generation.

Melatonin and other indole derivatives might thus play a role in the treatment and prevention of neurodegenerative disorders caused by oxidative stress and reactive oxygen species.

Combining the structural features of the indole and the polycyclic cage structures, both with well documented pharmacological effects, could indeed provide the basis for novel structures with the potential to act via multiple modes of action, addressing the multi-component aspects of pathology of neurodegenerative diseases.
3. Introduction

Medicinal chemists today are facing an ever increasing challenge to design new therapeutic agents for the treatment of human disease. For many years the main focus for discovering new drugs consisted of taking a lead structure and developing a chemical program for finding analogues exhibiting the desired pharmacodynamic properties. These drug discovery methods are now being supplemented by more direct approaches made possible by the understanding of the molecular processes involved in the underlying disease. In this perspective, the initial point in drug design is the molecular target (receptor, enzyme) in the body instead of the existence of an already known lead structure (Cohen, 1996).

Computer aided molecular drug design and graphics (molecular modelling) has its origins in the 1980's and can be simply considered as a range of computational techniques that are based on theoretical chemistry methods and experimental data. It can be used either to analyse molecules and molecular systems or to predict molecular and pharmacodynamic properties.

These computational methods and molecular visualisation techniques currently available provide extensive insight into the precise molecular features that are responsible for the regulation of biological processes: molecular geometries, atomic and molecular electronic aspects and hydrophobic forces. All these structural characteristics are of great importance in the understanding of structure-activity relationships and in rational drug design (Cohen, 1996).

3.1. The substrate binding site of nNOS

Raman et al. (2001) described the crystal structure of 3-bromo-7-nitroindazole (3-Br-7-NI, 1OM5, fig. 3.1) complexed with the catalytic heme domain of nNOS. Both 7-nitroindazole (7-NI) (Babbedge et al., 1993; Moore et al., 1993; Wolff et al., 1994) and 3-Br-7-NI (Bland-Ward & Moore, 1995) are potent inhibitors of all three NOS isoforms in vitro. Biochemical studies have shown that these compounds not only
Molecular modelling: Chapter 3

compete with L-Arginine but also for the cofactor tetrahydrobiopterin (H₄B)-binding site (Alderton et al., 1998; Mayer et al., 1994; Wolff & Gribin, 1994). These inhibitors exhibit a high level of specificity for nNOS in vivo and expectedly fail to produce discernible changes in systemic blood pressure (Moore et al., 1993; Handy & Moore, 1998).

![Structural formulas of the substrate and ligands used in the above crystallographic studies.](image)

**Figure 3.1:** Structural formulas of the substrate and ligands used in the above crystallographic studies.

Although the exact mechanism for the specificity of these inhibitors to nNOS in vivo is poorly understood, it is thought that differences in uptake pathways of different cell types may play a role. More importantly, 7-NI and 3-Br-7-NI have been shown to be neuroprotective in animal models of stroke (Nanri et al., 1998) and Parkinson's disease (Przedborski et al., 1996; Zhang et al., 2000). Therefore, understanding the molecular basis of 3-Br-7-NI recognition by NOS will aid in the development of new isoform-selective inhibitors that can be used in the treatment of neurodegenerative disorders involving NO-mediated neurotoxicity.

### 3.1.1. Molecular recognition of 3-Br-7-NI at the substrate binding

The active-site structure of nNOS is shown in fig. 3.2. The substrate, L-Arg, is positioned over the heme where H-bonds with Trp 587, Tyr 588, Glu 592, Gln 478 and Asp 597 help to orient the substrate for regioselective hydroxylation by, presumably, a Fe-linked O atom. The essential cofactor, H₄B, is bound at the intersubunit interface. Note that H₄B and the R-amino group of L-Arg both H-bond with the same heme propionate (Raman et al., 2001).
Presumably, 3-Br-7-NI displaces L-Arg from the active site despite the fact that 3-Br-7-NI bears no structural similarity to L-Arg. To understand how 3-Br-7-NI binds to NOS, Li et al., 2003 solved the crystal structure of 3-Br-7-NI bound to the catalytic heme domain of nNOS at 2.30 Å resolution. 3-Br-7-NI occupies the site where L-Arg is normally bound (fig. 3.3). The orientation of the inhibitor is unambiguous due to the bulky density of the bromine atom used as a guide in positioning the inhibitor in the substrate cavity. When compared with L-Arg, 3-Br-7-NI is relatively planar and stacks parallel within van der Waals contact distance to the heme plane (fig. 3.3), and hydrogen-bonds with Met 589 and Heme.

Figure 3.2: A molecular model of the nNOS active and H₄B binding sites (purple). Note that L-Arg (purple) and H₄B both H-bond with the same heme propionate.

Figure 3.3: Molecular model where 3-Br-7-NI (green) displaces L-Arg from the active site.
3-Br-7-NI, being an aromatic heterocycle, albeit $\pi$-deficient at carbon atoms due to the number of ring N atoms, probably derives some of its binding energy from the $\pi-\pi$ stacking interactions with the heme and many nonbonded contacts it entertains with the protein. Thus, the 3-Br-7-NI ring mimics the L-Arg guanidinium in both electrostatic stabilisation and $\pi$-stacking with the heme ring.

3.1.2. Implications of the binding site of NOS for drug design

There are many instances in which a protein differentiates between nearly identical inhibitors. NOS for instance can recognise the different arginine-based inhibitors by utilising the same set of contacts that are made to L-Arg alongside new interactions made with the substituent. Important to this interaction is the H-bonding potential of the Glu-592 side chain that participates in type I or type II interactions (Ippolito et al., 1990; Singh et al., 1987) and whether amidino (Li et al., 2001), guanidino or ureido (Li et al., 2000) groups are present in the inhibitor.

In the case of 3-Br-7-NI, it completely removes Glu-592 from engaging in direct H-bonded contact with the inhibitor. Secondly, it competes for both the substrate and cofactor binding sites at the same time. Due to this, 3-Br-7-NI is able to occupy one site and subsequently alter the specificity of a second site. From a study conducted by Raman et al. (2001) it was stated that an inhibitor which avoids H-bonded contact with one of the heme propionates, can serve as a potential template for designing drugs for isoform specificity. This phenomenon also has important implications for structure-based drug design. The target protein is usually treated as a binding surface template from which novel compounds with complementary shape and chemistry arise. In the conventional setting, a rigid geometry is assumed for the binding site, and this would not have predicted the binding of 3-Br-7-NI to NOS. The fact that Glu-592 adopts a new conformation in the 3-Br-7-NI complex has provided a structural basis for introducing knowledge-based dynamics information into drug-design strategies for NOS. It also emphasise the importance of dynamics, however small, in making a substantial contribution to the information content regarding how a target recognises a ligand. The authors have demonstrated that, although 3-Br-7-NI targets the substrate and cofactor-binding sites of NOS, its high specificity is garnered by adapting to a unique and altered protein conformation. The ability of 3-Br-7-NI to exploit this characteristic phenomenon provides a significant insight for the further development of therapeutically important isoform-specific NOS inhibitors (Raman et al., 2001).
3.2. Methodology

The ligandfit module of Cerius²® (2002) is a molecular modelling program capable of determining possible sites for ligand binding. The PDB file of 1OM5, containing the coordinates for the neuronal NOS enzyme co-crystallised with the inhibitor, 3-Br-7-Ni, was downloaded from RCSB Protein Data Bank (Li et al., 2003). The structure of the protein and docked ligand was used to generate an active site model (fig. 3.4) for the neuronal NOS enzyme utilising the Ligandfit® module of Cerius²® (2002). The DREIDING2.21 force field and Gasteiger charges were used throughout the experiment and all other values were set to default unless otherwise specified.

![Figure 3.4: 1OM5 with the active site of nNOS (yellow) as determined by site search in trace rendering as calculated with Ligandfit®.](image)

This active site model was used to investigate a series of polycyclic structures. The different conformations of the compounds selected for synthesis (fig. 3.5, compound 1-19) generated by Catalyst 4.9® were exported to Cerius²® as a SD (structural data) file in order to facilitate docking of these conformations into the determined active site of the enzyme.
Figure 3.5: Proposed structures for *in vitro* evaluation for NOS activity

Before the docking was performed, the Monte Carlo parameters were set to 1000 to limit the amount of additional conformers generated and evaluated to a maximum of 1000. The default parameters were used in all other cases. The results of the fits were included into a study table and the compounds were sorted in order of the consensus score, Ligscore1 and Ludi score accordingly. The highest scores of the 5 best conformers of each compound, and thus best overall fit in the active site, were selected and evaluated for theoretical interaction with the NOS enzyme. The different drug conformations were fitted into the site to obtain orientation and hydrogen-bonds interactions (fig 3.6).
Figure 3.6: Possible interactions in the active site of all planned compounds for synthesis. Ligands were kept in default colours and adjacent amino acids are highlighted in either red or blue and hydrogen-bonds are indicated in yellow.
3.3. Results and Discussion

Substrates (L-Arg or L-NHA) bind to the active site via an extensive hydrogen bond network involving both guanidinium and amino acid moieties to the surrounding enzyme residues. Nω-Hydroxy-L-arginine (L-NHA) binds to the nNOS active site in a similar way to that of L-Arg (Li et al., 2002). The protein-ligand interactions can be divided into two sites. One is the amino acid binding pocket where one of the carboxylate oxygen atoms of L-NHA accepts H-bonds from Tyr588 and Gln478 and the other carboxylate oxygen is within H-bonding distance of Asp597. The R-amino nitrogen forms H-bonds forming a bridge between the Glu592 side chain and one of the heme propionates.
Molecular modelling: Chapter 3

The second site is right above the heme plane where the guanidine group maintains three hydrogen bonds via its bridging nitrogen and its unsubstituted terminal nitrogen (NH2) to the Glu592 side chain and the Trp587 carbonyl oxygen. The hydroxyl group of L-NHA does not coordinate to the heme iron but instead points away from it towards the backbone amide of Gly586 to form a weak H-bond or nonbonded contact. The L-NHA binding mode in nNOS is essentially identical to what has been reported for human eNOS (Fischmann et al., 1999) and murine iNOS (Crane et al., 2000).

Table 3.2: Summary of observed H-bond interactions between the best conformers of the compounds and adjacent amino acids.

<table>
<thead>
<tr>
<th>Compound name</th>
<th>H-bond interaction</th>
<th>Compound name</th>
<th>H-bond interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound 1</td>
<td>Gln478, Trp587</td>
<td>Compound 11</td>
<td>Tyr588, Trp587</td>
</tr>
<tr>
<td>Compound 2</td>
<td>Gln478</td>
<td>Compound 12</td>
<td>Heme</td>
</tr>
<tr>
<td>Compound 3</td>
<td>Heme</td>
<td>Compound 13</td>
<td>Asn569, Trp587, Tyr588</td>
</tr>
<tr>
<td>Compound 4</td>
<td>Trp587</td>
<td>Compound 14</td>
<td>Gln478</td>
</tr>
<tr>
<td>Compound 5</td>
<td>Trp587, Gln478</td>
<td>Compound 15</td>
<td>Gln478</td>
</tr>
<tr>
<td>Compound 6</td>
<td>Heme</td>
<td>Compound 16</td>
<td>Heme, Gln478</td>
</tr>
<tr>
<td>Compound 7</td>
<td>Heme, Gln478</td>
<td>Compound 17</td>
<td>Heme, Gln478</td>
</tr>
<tr>
<td>Compound 8</td>
<td>Gln478</td>
<td>Compound 18</td>
<td>Glu592, Gln478</td>
</tr>
<tr>
<td>Compound 9</td>
<td>Gln478, Trp587</td>
<td>Compound 19</td>
<td>Heme, Glu592</td>
</tr>
<tr>
<td>Compound 10</td>
<td>Gln478, Tyr588</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
In all cases the indole ring was oriented either parallel or towards the heme in the binding cavity, with the cage structure located near the entrance cavity. A few of the test compounds formed hydrogen bonds with the amino acids necessary for activity, Tpr587, Glu592 and heme, and it was hypothesised that these compounds might show NOS inhibitory activity. Compounds that formed hydrogen-bonds with Tyr 588, Gln 478 and Asp 597 could also be active since these amino acids play only a role in the stabilisation and orientation of ligands in the cavity. From the docking studies it is clear that all the test compounds formed one or more H-bonds with heme, amino acids necessary for activity or stabilising amino acids.

3.4. Conclusion

From the docking study, it is clear that H-bonds are necessary for NOS activity. Since 3-Br-7-NI is capable of altering the conformation of the binding amino acids within the active site, the novel compounds may exhibit the same phenomenon.

The compounds that exhibited the best inhibition activity towards NOS in silico were compounds 1, 4, 5, 9, 11, 18, 19, since they formed hydrogen bonds with the amino acids necessary for activity. However in vitro studies need to be conducted to determine the validity of the assumption and potential of these compounds for neuroprotection.
4. Instrumentation

**Mass spectrometry (MS):** An analytical VG 70-70E mass spectrophotometer with electron ionisation (EI) at 70 eV was used for MS and high resolution mass spectrometry (HRMS). Relevant spectra are included in annexure 1.

**Infrared (IR) absorption spectrophotometry:** IR spectra were recorded on a Nicolet 470 FT-IR spectrophotometer, incorporating the samples in KBr pellets. Relevant spectra are included in annexure 1.

**Melting point (mp):** Melting points were measured using a Gallenkamp melting point apparatus and capillary tubes.

**Nuclear magnetic resonance spectrometry (NMR):** A Varian VXR300 spectrometer was used to obtain \(^1\)H and \(^{13}\)C spectra. \(^1\)H spectra were recorded at a frequency of 300.075 MHz and \(^{13}\)C spectra at 75.462 MHz, in a 7 Tesla magnetic field with tetramethylsilane (TMS) as internal standard and a bandwidth of 100 Hz at 24 KG applied for \(^1\)H and \(^{13}\)C decoupling. All chemical shifts are reported in parts per million (ppm) relative to TMS (δ = 0). The following abbreviations are used to indicate multiplicities of signals: s – singulet, bs – broad singulet, d – doublet, t – triplet and m – multiplet. Spectra of selected compounds are included in annexure 1.

4.1. Chromatographic methods

Mobile phases used were prepared on a volume-to-volume basis (v/v). Mobile phases containing chloroform, ethanol and ethylacetate were mostly used and when necessary new combinations were made using the Prism model of Nyiredy et al. (1985). Ultraviolet light (UV 254 nm and UV 366 nm), 2% ninhydrine solution and iodine vapours were used for visualisation on thin layer chromatography.

**Thin layer chromatography:** TLC was used to monitor all chemical reaction.
Column chromatography: Separation and purification of product mixtures were done using flash chromatography (Still et al., 1978) on glass columns filled with silica gel Merck® (0.063-0.200 mm).

4.2. Selection of compounds

From the general SAR of the polycyclic and indole derivatives and the results obtained from molecular modelling, the structures included in table 4.1 were selected for synthesis and evaluation.

Table 3.1: Compounds evaluated and synthesised in this study.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Name</th>
<th>Structure</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.02,6.03,10.05,9]undecane-11-one</td>
<td><img src="image1" alt="Structure" /></td>
</tr>
<tr>
<td>2</td>
<td>8-[3-(2-aminoethyl)indole]-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane</td>
<td><img src="image2" alt="Structure" /></td>
</tr>
<tr>
<td>3</td>
<td>3-hydroxy-4-[3-(2-aminoethyl)indole]-azahexacyclo[5.4.1.02,6.03,10.05,9,08,11]dodecane</td>
<td><img src="image3" alt="Structure" /></td>
</tr>
<tr>
<td>4</td>
<td>8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.02,6.03,10.05,9]undecane</td>
<td><img src="image4" alt="Structure" /></td>
</tr>
</tbody>
</table>
4.3. General synthetic route

The well-described Cookson's diketone, pentacyclo[5.4.0.0²6.0³,10.0⁵,9]undecane-8,11-dione (A, fig. 3.3), served as initial basis in all further synthetic preparations and were prepared in bulk according to literature (Cookson et al., 1958, 1964). This reaction involved Diels-Alder adduct formation and subsequent photocyclisation to yield the polycyclic cage structure. The respective primary amine bases were then conjugated to this diketone by means of reductive amination (nucleophilic addition) to form the corresponding carbinolamine (B), followed by Dean-Stark dehydration. The intermediate imine (C) was then reduced with NaBH₄ and NaBH₃CN in anhydrous methanol-THF to the final oxa-amine (D) and aza-amine (E) respectively.
4.3.1. Pentacyclo[5.4.0.0².⁶.0³.⁹.0⁵.⁵]undecane-8,11-dione (A)

p-Benzquinone (10 g (0.0925 mole) purchased from Sigma-Aldrich was dissolved in dried benzene (100 ml) and protected from light by means of aluminium foil. The mixture was placed in an ice bath and allowed to cool down to 0-5°C.

Freshly monomerised cyclopentadiene (12.453 ml, 0.0925 mole) was added stoichiometrically in 1 ml aliquots to the reaction mixture while the temperature remained at approximately 0°C. This was done to prevent the formation of the diadduct. After the addition of the cyclopentadiene the reaction mixture was removed from the ice bath, protected from light and stirred for another hour while the reaction was monitored by means of thin layer chromatography (TLC). After confirmation that all the p-Benzquinone was fully converted to the Diels-Alder adduct, the mixture was treated with activated charcoal and filtered through celite. The excess solvent was removed in vacuo to 10 ml and the rest was allowed to evaporate in a dark fume cupboard to afford the Diels-Alder adduct as light yellow crystals. The crystals were dissolved in ethyl acetate (4 g in 100 ml) and irradiated in a photochemical reactor with UV light for
approximately six hours. Decolouration of the solution indicated that cyclisation had occurred and the solvent was removed in vacuo. Evaporation of this solution afforded a light yellow residue that was purified by using Soxhlet extraction with cyclohexane to yield the diketone as fine, white powder. (Yield: 12.9 g, 80.05 %).

Spectral data were identical to the corresponding data reported previously (Cookson et al., 1958).

4.3.2. Pentacyclo[5.4.0.0²⁶.0³¹⁰.0⁵⁸]undecane-8-one (J)

A mixture of pentacyclo[5.4.0.0²⁶.0³¹⁰.0⁵⁸]undecane-8,11-dione (A; 3 g, 17.22 mmole), ethylene glycol (1.2 g) and p-toluenesulfonic acid (20 mg, 0.01 mmole) in benzene (30 ml) was stirred under reflux for 5 hours (fig. 3.4). The reaction mixture was cooled and treated with activated charcoal which was subsequently removed by filtration. In vacuo removal of benzene yielded the monoethylene-acetal (F) as colourless crystals. A suspension of the acetal (F) was made in dry ether (10 ml) and over a period of 30 minutes gradually added to a suspension of lithium aluminium hydride (LAH; 300 mg) in dry ether (6 ml). The reaction mixture was refluxed for 2 hours and then cooled to 0°C. After reduction, excess LAH was deactivated with aqueous ammonium chloride and the organic phase concentrated in vacuo to afford clear homogenous oil (G). Hydrolysis of the acetal was done by stirring the oil in 6% hydrochloric acid (50 ml) for 2 hours at room temperature. Loss of the initial blue colour indicated complete hydrolysis upon which the reaction mixture was diluted with water (50 ml) and extracted with dichloromethane (5 x 20 ml). In vacuo removal of the organic solvent gave the hydroxy-ketone (H). A mixture of the hydroxy-ketone and hydrazine hydrate (5 ml) in diethylene glycol (60 ml) was stirred at 120°C for 1.5 hours. Potassium hydroxide (2 g) was added and the excess hydrazine and water distilled until the temperature reached 190°C, at which point the reaction mixture was refluxed for a further 3 hours. Dichloromethane extraction of the distillate yielded the pure alcohol (I) which was dissolved in 94% acetic acid (60 ml) and added to a mixture of chromium trioxide (4 g) in water (6 ml). The mixture was stirred at 90°C for 4 hours, cooled, diluted with water (300 ml) and extracted with dichloromethane (4 x 40 ml). After successive washes with water (3 x 100 ml), the organic phase was removed in vacuo to afford the desired monoketone (J).

Spectral data were identical to the corresponding data reported previously (Dekker & Oliver, 1978).
Synthetic procedures: Chapter 4

Figure 3.4: Synthesis of the monoketone (J) via the modified Huang-Minlon reduction of the hydroxy-ketone (H).

4.3.3. 8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.0².0⁶.0¹⁰.0¹⁵.0⁸]undecane-11-one

Pentacyclo[5.4.0.0².0⁶.0¹⁰.0¹⁵.0⁸]undecane-8,11-dione (3 g, 17.22 mmole) was dissolved in tetrahydrofurane (THF; 20 ml) and cooled on an ice bath. 3-(2-aminoethyl)indole, 3.31 g; 20.664 mmole, was dissolved in 40 ml tetrahydrofurane (THF) and slowly added to the reaction mixture while it was constantly stirred for 24 hours at room temperature. The THF was concentrated in vacuo to afford the hydroxylamine as a yellow oil. Dean-Stark dehydration in anhydrous benzene afforded the Schiff-base (8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.0².0⁶.0¹⁰.0¹⁵.0⁸]undecane-11-one as a yellow oil. Purification by consecutive flash columns (silica gel stationary phase, 7:3 THF:EtOAc as eluent and silica gel stationary phase, 1:1:1 EtOAc:DCM:PE as eluent) afforded a pure yellow powder. (2.112 g, 38.8 %).
Physical Data: \( \text{C}_{21}\text{H}_{20}\text{N}_2\text{O}; \text{MS} \text{ m/z (Spectrum 1) = 316(M')} \), 234, 221, 205, 186, 174, 145, 143, 130, 117, 103, 91, 81, 77, 66, 51, 44, 39, 28; \( \text{\( ^1\text{H NMR (Spectrum 2, DMSO)} \delta = 1.35-1.80 \) (2 x m, 2H), 1.93-2.48 (m, 2H), 2.50-3.61 (4 x m, 9H), 6.89-7.58 (m, 4H); \text{\( ^{13}\text{C NMR (Spectrum 3, DMSO)} \delta = 25.06 \) (CH), 26.28 (CH), 30.36 (CH), 38.15 (CH), 39.90 (CH\( _2 \)), 43.39 (CH), 44.19 (CH), 54.38 (CH), 66.95 (CH\( _2 \)), 136.20 (C), 212.89 (C).} \)

4.3.4. 8-[3-(2-aminoethyl)indole]-8,11-oxapentacyclo[5.4.0.0\( ^2 \).0\( ^3 \).0\( ^10 \).0\( ^5 \).0\( ^9 \)]undecane

8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.0\( ^2 \).0\( ^3 \).0\( ^10 \).0\( ^5 \).0\( ^9 \)]undecane-11-one (700 mg, 2.215 mmole) was dissolved in anhydrous methanol (5 ml) and tetrahydrofurane (THF; 21 ml). To the resulting solution was added sodium borohydride (210 mg; 5.55 mmol) portionwise and it was stirred overnight at room temperature for effective reduction. The reaction mixture was concentrated in vacuo and water was added to the residue (100 ml). The mixture was extracted with dichloromethane (4 x 50 ml) and the combined fractions were washed with water (3 x 100 ml), dried over anhydrous magnesium sulphate, filtered and concentrated in vacuo to obtain a yellow powder. (496 mg, 70.3 %).

Physical Data: \( \text{C}_{21}\text{H}_{22}\text{N}_2\text{O}; \text{\( ^1\text{H NMR (Spectrum 4, DMSO)} \delta = 0.964 \) (d, 1H, \( J = 10.41 \) Hz), 1.35 (s, 1H), 1.54 (d, 1H, \( J = 10.47 \) Hz), 2.07-2.23 (m, 4H), 2.49 (s, 5H), 2.81-2.88 (m, 2H), 3.32-3.39 (m, 2H), 3.61 (s, 2H), 6.28 (s, 2H), 6.95-7.54 (3 x m, 3H); \text{\( ^{13}\text{C NMR (Spectrum 5, DMSO)} \delta = 30.37 \) (CH), 34.08 (CH\( _2 \)), 38.11 (CH), 42.32 (CH), 42.35 (CH), 45.22 (CH), 70.47 (CH), 71.50 (CH), 118.12 (C).} \)

4.3.5. 3-hydroxy-4-[3-(2-aminoethyl)indole]-azahexacyclo[5.4.1.0\( ^2 \).0\( ^3 \).0\( ^10 \).0\( ^5 \).0\( ^8 \).0\( ^11 \)]dodecane

8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.0\( ^2 \).0\( ^3 \).0\( ^10 \).0\( ^5 \).0\( ^9 \)]undecane-11-one (700 mg, 2.215 mmole) was dissoloe in anhydrous methanol (35 ml) and acetic acid (2.1 ml). To the resulting solution was added sodium cyanoborohydride (280 mg; 4.46 mmole)
portionwise and it was stirred for 6 hours at room temperature for effective reduction. The reaction mixture was concentrated in vacuo and water was added to the residue (100 ml). The resulting suspension was stirred, and an excess solid sodium bicarbonate was added portionwise until evolution of carbon dioxide ceased. The mixture was extracted with dichloromethane (4 x 50 ml) and the combined fractions were washed with water (3 x 100 ml), dried over anhydrous magnesium sulphate, filtered and concentrated in vacuo to obtain a yellow powder. (237 mg; 33.6%).

Physical Data: C_{21}H_{22}N_{2}O; MS m/z (Spectrum 6) = 318 (M^+), 256, 236, 188, 149, 130, 117, 111, 97, 83, 81, 69, 57, 43, 28; ^1H NMR (Spectrum 7, CDCl_3) δ = 1.67-1.85 (m, 1H), 2.07-2.88 (3 x m, 12H), 6.99-7.50 (3 x m, 3H); ^13C NMR (Spectrum 8, CDCl_3) δ = 30.37 (CH), 36.09 (CH), 37.78 (CH_2), 38.67 (CH), 41.09 (CH), 41.24 (CH), 42.32 (CH), 43.04 (CH_2), 43.80 (CH), 44.03 (CH), 44.52 (CH), 45.15 (CH), 49.15 (CH), 53.15 (CH), 54.24 (CH), 55.56 (CH), 70.46 (CH), 79.98 (CH), 111.30 (CH), 118.16 (C), 214.79 (C).

4.3.6. 8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0.0^{2,6}.0^{3,10}.0^{5,9}]undecane

The monoketone (J, 975 mg, 6.085 mmole) was dissolved in tetrahydrofuran (THF; 30 ml) and cooled on an ice bath. 3-(2-aminoethyl)indole, 1.95 g; 12.171 mmole) was dissolved in 30 ml tetrahydrofuran (THF) and slowly added to the reaction mixture while it was constantly stirred for 24 hours at 0°C. After 24 hours the reaction mixture was removed from the ice bath and refluxed for 84 hours. The THF was concentrated in vacuo to afford the hydroxylamine as a yellow oil. Dean-Stark dehydration in anhydrous benzene afforded the Schiff-base (8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0^{2,6}.0^{3,10}.0^{5,9}]undecane as a yellow oil. Purification by flash chromatography (silica gel stationary phase, 5:2:2 CHCl_3:EtOH:EtOAc as eluent)
afforded a pure yellow oil. A pure yellow precipitate was obtained after drying in a vacuum oven. (1.625 g, 88.3 %).

Physical Data: \( \text{C}_{21}\text{H}_{22}\text{N}_2; \) IR \( \nu_{\text{max}} \) (Spectrum 9) = 3407, 2948, 2859, 1684, 1454, 1354, 1231, 1105, 734 cm\(^{-1}\); MS m/z (Spectrum 10) = 302 (M\(^+\)), 172, 160, 144, 130, 117, 115, 106, 94, 79, 65, 53, 41, 28; \(^1\)H NMR (Spectrum 11, CDCl\(_3\)) \( \delta = 1.21 \) (s, 2H), 1.35 (m, 1H), 1.71 (m, 1H), 2.16-2.36 (m, 3H), 2.47-2.77 (m, 4H), 2.81-2.90 (m, 1H), 2.30-3.10 (m, 2H), 3.55 (t, 1H, \( J = 7.42 \) Hz), 3.60-3.74 (m, 1H), 6.94-7.63 (4 x m, 5H), 8.51 (bs, 1H); A mixture of two isomers were obtained and the signals of the second isomer is indicated in brackets. \(^{13}\)C NMR (Spectrum 12, CDCl\(_3\)) \( \delta = 27.12 \) (27.27); (CH\(_2\)), 30.42 (30.69); (CH\(_2\)), 35.15 (no duplicate signal); (CH), 36.16 (36.59); (CH\(_2\)), 38.40 (38.47); (CH), 39.18 (39.69); (CH), 42.65 (43.20); (CH), 43.24 (43.45); (CH), 44.00 (no duplicate signal); (CH), 45.02 (no duplicate signal); (CH), 46.02 (no duplicate signal); (CH), 47.03 (no duplicate signal); (CH), 47.42 (47.51); (CH), 51.52 (no duplicate signal); (CH), 53.20 (53.29); (CH\(_2\)), 111.03 (111.06); (CH), 114.16 (114.24); (CH), 118.81 (118.97); (CH), 121.91 (121.96); (CH), 127.51 (127.53); (C), 136.40 (136.43); (C), 181.54 (181.78); (C); HRMS calcd. 302.1783, found 302.1776.

4.3.7. 8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0\(^2\).6.0\(^3\).10.0\(^5\).8]undecane

8-[3-(2-aminoethyl)indole]-pentacyclo[5.4.0\(^2\).6.0\(^3\).10.0\(^5\).8]undecane (777 mg, 2.57 mmole) was dissolved in anhydrous methanol (5 ml) and tetrahydrofuran (THF; 21ml). To the resulting solution was added sodium borohydride (110 mg; 2.9 mmol) portionwise and it was stirred overnight at room temperature for effective reduction. The reaction mixture was concentrated \textit{in vacuo} and water was added to the residue (100 ml). The mixture was extracted with dichloromethane (4 x 50 ml) and the combined fractions were washed with water (2 x 100 ml), dried over anhydrous magnesium sulphate, filtered and concentrated \textit{in vacuo} to obtain a yellow oil. Purification by consecutive flash columns
(silica gel stationary phase, 5:2:2 CHCl₃:EtOAc:EtOH as eluent and silica gel stationary phase, 7:3 EtOH:EtOAc as eluent) afforded a pure white powder. (592 mg, 75.6%).

Physical Data: C₂₁H₂₄N₂; IR νₘₐₓ (Spectrum 13) = 3407, 2955, 2863, 1613, 1446, 1346, 1227, 1109, 737 cm⁻¹; MS m/z (Spectrum 14) = 304(M⁺), 174, 145, 131, 117, 115, 79, 67; ¹H NMR (Spectrum 15, CDCl₃): δ 0.94 (m, 1H), 1.15 (d, 1H, J = 10.24 Hz), 1.42 (bs, 1H), 1.66 (d, 1H, J = 9.84 Hz), 2.13 (d, 1H, J = 11.95), 2.22 (m, 4H), 2.53 (m, 4H), 2.76 (t, 1H, J = 3.4 Hz), 2.96 (m, 4H), 7.11 (d, 1H, J = 1.13 Hz), 7.10 (m, 1H), 7.13 (m, 1H), 7.33 (d, 1H, J = 7.83 Hz), 7.63 (d, 1H, J = 7.77 Hz), 8.22 (bs, 1H); ¹³C NMR (Spectrum 16, CDCl₃): δ = 26.22 (CH₂), 28.69 (CH₂), 34.67 (CH₂), 36.20 (CH), 37.70 (CH), 40.73 (CH), 41.77 (CH), 41.92 (CH), 44.10 (CH), 44.62 (CH), 47.23 (CH), 49.24 (CH), 61.67 (CH), 111.04 (CH), 114.31 (C), 118.92 (CH), 119.11 (CH), 121.77 (CH), 121.86 (CH), 127.53 (C), 136.40 (C); HRMS calcd. 304.1939, found 304.1948.

4.3.8. Additional cage structures

As indoles with an aliphatic amine group could not be obtained from chemical suppliers, we planned to conjugate the known cage structure with aminopropanol, as linker, and then with selected indole carboxylic acids to obtain polycyclic indole esters. This however did not realise as expected, but novel rearranged cage structures were obtained.

4.3.8.1. 3-hydroxy-4,5-(1,3-oxazinane)azahexacyclo[5.4.1.0²⁸.0³¹⁶.0⁵₈.0⁶¹₁]dodecane

Pentacyclo[5.4.0.0²⁸.0³¹⁶.0⁵₈]undecane-8,11-dione (3 g, 17.22 mmole) was dissolved in tetrahydrofuran (THF; 30 ml) and cooled on an ice bath. 3-Aminopropanol (1.31 ml; 17.22 mmole) was dissolved in 6 ml tetrahydrofuran (THF) and slowly added to the reaction mixture while it was constantly stirred for 2 hours at 0°C. After 2 hours the carbinolamine precipitated. The THF was removed in vacuo and the product was dehydrated by Dean-Stark in anhydrous benzene. The benzene was concentrated in
Synthetic procedures: Chapter 4

*Vacuo* to 10 ml and the unexpected 3-hydroxy-4,5-(1,3-oxazinane) azahexacyclo[5.4.1.0²,8.0³,10.0⁵,9.0⁶,11]dodecane crystallised from it (2.49 g, 62.5%).

**Physical Data:** C₁₄H₁₇N₂O₂; mp. 168-172 °C; IR ν<sub>max</sub> (Spectrum 17) = 3437, 3088, 2962, 2844, 1628, 1483, 1424, 1316, 1161, 1120, 1064, 949, 864, 663, 585; MS m/z (Spectrum 18) = 231(M⁺), 214, 202, 187, 174, 151, 136, 117, 99, 91, 69, 55, 41, 28; ¹H NMR (Spectrum 19, CDCl₃) δ = 1.51 (d, 1H, J = 10.57), 1.55-1.75 (m, 2H), 1.79 (d, 1H, J = 10.54), 2.52-3.01 (3 x m, 9H), 3.67-3.85 (2 x m, 2H), 4.71 (bs, 1H); ¹³C NMR (Spectrum 20, CDCl₃) δ = 24.25 (CH₂), 41.09 (CH₂), 41.55 (CH), 41.63 (CH), 42.42 (CH₂), 42.98 (CH), 44.04 (CH), 44.59 (CH), 45.81 (CH), 53.08 (CH), 55.04 (CH), 62.69 (CH₂), 101.63 (C); HRMS calcd. 231.1259, found 231.1250.

**4.3.8.2. Proposed mechanism for rearrangement**

The proposed rearrangement is similar one described for the acid-catalysed acetal formation by reaction of a ketone with an alcohol described in McMurray (1999). Hydronium ions are formed during the reaction and activate the imine nitrogen and thus the imine carbon through electron delocalisation. Once the carbonyl carbon is activated, the hydroxyl group of the 3-aminopropanol is folded back towards the cage structure to launch a nucleophilic attack. After ring closure, the free electron pair on the nitrogen is in close proximity of the adjacent carbonyl carbon and thus available for a further nucleophilic attack to afford the aza compound fig. 3.5.
Figure 3.5: Proposed rearrangement mechanism to form 3-hydroxy-4,5-(1,3-oxazinane)-4-azahexacyclo[5.4.1.0^2.6.0^3.10.0^5.9.0^8.11]dodecane.

### 4.3.8.3. X-ray crystallography

The aim of x-ray crystallography is to obtain a three dimensional molecular structure from a crystal. A purified sample at high concentrations is crystallised and the crystals are exposed to an x-ray beam. The resulting diffraction patterns can then be processed, initially to yield information about the crystal packing symmetry and the size of the repeating unit that forms the crystal. This is obtained from the pattern of the diffraction patterns. The intensities of the patterns can be used to determine the structure parameters from which a map of the electron density can be calculated. Various methods can be used to improve the quality of this map until it is of sufficient clarity to permit the building of the molecular structure. The resulting structure is then refined to fit the map more accurately and to adopt a thermodynamically favoured conformation. (Smyth & Martin, 2000).

3-Hydroxy-4,5-(1,3-oxazinane)-4-azahexacyclo[5.4.1.0^2.6.0^3.10.0^5.9.0^8.11]-dodecane was crystallised from benzene at 4°C in a dark walk-in fridge. A single crystal of size 0.07 x 0.11 x 0.14 mm was used and cooled in a stream of nitrogen vapor to 113 K. Space
Synthetic procedures: Chapter 4

group Pbca, \( a = 12.3763 \) (7), \( b = 11.6597 \) (6), \( c = 15.0539 \) (8) Å, \( \alpha = 90^\circ \), \( \beta = 90^\circ \), \( \gamma = 90^\circ \) with \( Z = 8 \) formula units of \( \text{C}_{14}\text{H}_{17}\text{NO}_{2} \); \( D_c = 1.414 \) g/cm\(^3\) was used. Intensity data were collected on an Enraf Nonius Kappa CCD diffractometer with graphite-monochromated Mo K\(\alpha\) radiation (\( \lambda = 0.71073 \) Å), \( \mu = 0.094 \) mm\(^{-1}\)). Refinement on \( F^2 \) converged to a weighted \( R \) value (\( wR_2 \)) of 0.1689 for all reflections. The conventional \( R \) factor was 0.054 for 2048 reflections with \( I > 2.0\sigma (I) \). A summary of the crystal data, data-collection and refinement parameters is included in (table 3.2)

An interesting aspect of the molecular structure is that the six-membered ring adopts a chair conformation. The packing is determined by two intramolecular hydrogen bonds between O12 and N17 of two enantiomers packed against each other (fig 4.6).

**Table 3.2: Summary of x-ray diffraction data.**

<table>
<thead>
<tr>
<th>Empirical formula</th>
<th>( \text{C}<em>{14}\text{H}</em>{17}\text{NO}_{2} )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formula weight</td>
<td>231.29</td>
</tr>
<tr>
<td>Crystal system</td>
<td>Orthorhombic</td>
</tr>
<tr>
<td>Space group</td>
<td>( \text{Pbca} )</td>
</tr>
<tr>
<td>( a ) (Å)</td>
<td>12.3763 (7) ( \lambda ) alpha = 90 deg</td>
</tr>
<tr>
<td>( b ) (Å)</td>
<td>11.6597 (6) ( \lambda ) beta = 90 deg</td>
</tr>
<tr>
<td>( c ) (Å)</td>
<td>15.0539 (8) ( \lambda ) gamma = 90 deg</td>
</tr>
<tr>
<td>( V ) (Å(^3))</td>
<td>2172.3 (2)</td>
</tr>
<tr>
<td>( Z )</td>
<td>8</td>
</tr>
<tr>
<td>( \mu ) (mm(^{-1}))</td>
<td>0.094 (MoK(\alpha))</td>
</tr>
<tr>
<td>( F(000) )</td>
<td>992</td>
</tr>
<tr>
<td>Reflections with ( I &gt; 2.0\sigma (I) )</td>
<td>1225</td>
</tr>
<tr>
<td>Calculated density (g/cm(^3))</td>
<td>1.414</td>
</tr>
<tr>
<td>Crystal dimensions (mm)</td>
<td>0.07 x 0.11 x 0.14</td>
</tr>
<tr>
<td>Temperature (K)</td>
<td>113</td>
</tr>
<tr>
<td>Theta Min-Max (Deg)</td>
<td>3.2, 25.7</td>
</tr>
<tr>
<td>( R_1 )</td>
<td>0.0573</td>
</tr>
<tr>
<td>( wR_2 )</td>
<td>0.1689</td>
</tr>
<tr>
<td>( S )</td>
<td>1.02</td>
</tr>
</tbody>
</table>
Figure 3.6: Structure of C_{14}H_{17}NO_{2} as determined by x-ray crystallography, showing intermolecular hydrogen bonds between the two enantiomers.

4.3.9. 8-Ethoxy-8-ethylamino-pentacyclo[5.4.0^{2,6}.0^{3,10}.0^{5,9}]undecane-11-one

Pentacyclo[5.4.0^{2,6}.0^{3,10}.0^{5,9}]undecane-8,11-dione (5 g, 28.70 mmole) was dissolved in ethanol (EtOH; 50 ml) and cooled on an ice bath. 2-Bromoethylamine hydrobromide (5.88 g; 28.70 mmole) was dissolved in 50 ml ethanol (EtOH) and slowly added to the reaction mixture while it was constantly stirred at 0°C. After 4 hours the reaction mixture was removed from the ice bath and refluxed for another 24 hours. The EtOH was removed in vacuo, followed by Dean-Stark dehydration in anhydrous benzene. After removal of benzene in vacuo, the compound was purified by recrystallisation in EtOH:ETOAc:PE (7:3:1) to afford the unexpected 8-Ethoxy-8-ethylamino-pentacyclo[5.4.0^{2,6}.0^{3,10}.0^{5,9}]undecane-11-one. (1.504 g, 21.13 %)
Physical Data: C_{15}H_{20}O_{3}; mp. 104 °C; IR ν_{max} (Spectrum 21) = 3444, 2962, 2881, 1729, 1472, 1443, 1394, 1324, 1227, 1164, 1060, 960, 938, 745, 537 cm^{-1}; MS m/z (Spectrum 22) = 248(M^+), 219, 203, 175, 145, 122, 117, 109, 91, 81, 66, 55, 41, 29; \textsuperscript{1}H NMR (Spectrum 23, CDCl\textsubscript{3}) δ = 1.08 (t, 3H, J = 7.07), 1.12 (t, 3H, J = 7.08 Hz), 1.49 (d, 1H, J = 10.99), 1.79 (d, 1H, J = 10.88), 2.30-2.92 (5 x m, 8H), 3.29-3.48 (2 x m, 4H); \textsuperscript{13}C NMR (Spectrum 24, CDCl\textsubscript{3}) δ = 14.65 (CH\textsubscript{3}), 15.59 (CH\textsubscript{3}), 36.21, 38.20 (CH\textsubscript{2}), 40.90, 41.83, 42.21, 42.77, 45.68, 49.81, 52.16, 56.52 (CH\textsubscript{2}), 59.29 (CH\textsubscript{2}), 107.04 (C), 214.25 (C); HRMS calcd. 248.1412, found 248.1388.

4.4. Conclusion and Discussion:

The synthesis of all compounds resulted in yields ranging between 21.13 % and 88.3 % and the lower yields could be attributed to the formation of various unidentified impurities. Various linkers were applied to obtain amides, esters or ethers, but rearrangement reactions to form novel polycyclic structures however predominated.

Varying success has thus been achieved with the synthesis of these compounds and its purification. Solubility and multiple reactions taking place made it difficult to obtain the compounds in pure form for characterisation and optimisation of these reactions for further use are thus essential.
The aim of this study was to design and synthesise a series of polycyclic indole derivatives and to evaluate these compounds for neuroprotective activity. A decrease in the production of free radicals, due to the inhibition of NOS, was indicative of neuroprotective activity.

It is hypothesised that the test compounds with an indole moiety may have the ability to be NOS inhibitors as well as free radical scavengers. Two assay procedures were carried out to evaluate these compounds for their possible neuroprotective potential. The first assay procedure to be employed was the oxyhemoglobin assay for the detection of NOS inhibition and the second was the NBT assay for lipid peroxidation.

5. Nitric oxide synthase determination

5.1. Introduction

Nitric oxide synthase (NOS) enzymes catalyses the NADPH- and O2-dependent conversion of L-Arginine (L-Arg) to L-citrulline and nitric oxide (NO). The most frequently applied assay for the detection of nitric oxide (NO) under aerobic conditions is the oxyHb assay. This method is based on the reaction of NO with oxyHb which leads to the formation of metHb and nitrate (equation 5.1), a reaction that also largely accounts for the inhibitory effect of hemoglobin on the biological effects of NO (Feelisch et al., 1996). The conversion of oxyHb to metHb is an indication of NOS activity by monitoring the absorbance difference between these two hemoglobin species.

The applicability of this method is primarily based on its sensitivity and specificity for NO under aerobic conditions, inexpensiveness, ease of implementation and for the rather modest technical requirements (Feelisch et al., 1996).

$$\text{oxyHb} + \text{NO} \rightarrow \text{metHb} + \text{NO}_3^-$$  \hspace{1cm} 5.1

In a aqueous solution under aerobic conditions, NO is highly unstable and susceptible to rapid reactions with oxygen (O$_2$), superoxide anions (O$_2^-$), thiols (RSH) and a variety of metal containing proteins (Feelisch et al., 1996). As is true for any method of NO quantification, the reaction of NO with the detection molecule should be more rapid than
that of the other competing species. In the oxyHb assay, this requirement is met by the high reaction rate between NO and oxyHb, which has been estimated to be 26 times faster than the auto oxidation of NO in aqueous solution (Hoshino et al., 1993). The quenching or scavenging effect of superoxides may be limited by the addition of superoxide dismutase (SOD), both to increase the trapping efficiency of oxyHb for NO and to prevent the potential oxidation of oxyHb to metHb (Sutton et al., 1976). Thiols will also not interfere with NO measurement since the reaction rate of NO/oxyHb is much faster than that of the reaction rate of NO/O₂ (Wink et al., 1994). The rapid reaction between NO and oxyHb has the advantage of almost stoichiometrically trapping NO under most experimental conditions. Therefore, the oxyHb assay is somewhat unique among methods for NO determination in that it is less subjected to constraints imposed by competing reactions with oxygen, superoxide or thiols.

The absolute UV spectra of oxyHb is characterised by an intense absorption Soret- or γ-band with a maximum at 415 nm and two weaker β- and α-bands with absorption maxima at 542 nm and 577 nm (Feelisch et al., 1996). Methemoglobin's γ-band has an absorption maximum at 405 nm and the α- and β-bands are only detectable under alkaline conditions at 575 and 540 nm, respectively. At certain wavelengths the absorption of metHb is thus more intense than that of oxyHb and vice versa. The differences between metHb's and oxyHb's spectral characteristics become evident when the spectra are superimposed (fig. 5.1).

The absorbance intensities of both species are only equal at a few discrete wavelengths equal. Such spectral points of identical absorbance intensity are the so-called isosbestic points and they do not change during the conversion of oxyHb to metHb. The absorbance difference at a given isosbestic point will stay zero throughout the entire reaction.
Figure 5.1: Superimposed absolute absorption spectra of oxyhemoglobin (oxyHb) and methemoglobin (metHb). Intersection points represent the isosbestic wavelengths at which the absolute absorbances of both species are identical (Feelisch et al., 1996).

Figure 5.2: An example of the changes in the absolute spectrum of an oxyHb containing solution upon NO-mediated conversion to metHb. Although the total concentration of hemoglobin remains constant, the spectroscopic features change as oxyHb is converted to metHb (Feelisch et al., 1996).
During this procedure, an absolute spectrum (fig. 5.1) is recorded with the sample and reference cuvettes containing oxyHb and vehicle, respectively. After the reaction is started, NO reacts with oxyHb to form metHb. The new spectra recorded over time will present the absolute spectra of varying mixtures of oxyHb and metHb (fig. 5.2).

The disadvantage of this procedure however, is that the actual concentrations of the individual hemoglobin derivatives can only be read from the absolute absorbance when complete conversion of oxyHb to metHb has occurred (Feelisch et al., 1996). In order to obtain information about the extent of conversion and thus the amount of NO generated, the vehicle is no longer used as a reference, but only the oxyHb containing solution is employed. Instead of using the contents of a second cuvette, the absorbance of the same cuvette at a second wavelength is chosen as a reference. If the light absorption properties of the sample at a specific wavelength are recorded against the reference wavelength (difference spectra) in a repetitive manner, the changes in absorbance will reflect the loss of oxyHb and the simultaneous formation of metHb (fig. 5.3). In addition to the isosbestic points, there are certain regions corresponding to the formation of metHb where the absorbance increases (between 370 nm and 410.5 nm with a maximum at 401 nm) and regions corresponding to the loss of oxyHb where absorbance decreases (e.g. between 410.5 nm and 472 nm with a minimum at 421 nm). From the difference spectra, the wavelength at which maximum change in absorbance occurs and a nearby isosbestic wavelength is usually subtracted from each other to determine metHb formation.
Figure 5.3: Repetitive scans of difference spectra. Spectra were recorded during conversion by NO of oxyHb to metHb illustrating maximum absorbance differences and isosbestic points (Feelisch et al., 1996).

The more NO is generated the larger the absorbance difference (ΔA) will be. This linear relationship between the absorbance difference (ΔA) and the amount of metHb formed is used to calculate the change in metHb concentration. In order to calculate the time dependent increase of metHb concentration, the absorbance difference between a wavelength of maximal absorbance change (e.g. 401 nm) and an internal reference wavelength (e.g. 410.5 nm or 421 nm) are measured as a function of time. The slope of the resulting curve is a measure of the increase in metHb concentration and thus NO formation or enzyme activity (fig. 5.4).
5.2. Experimental procedures

The study protocol was approved by the Ethics Committee for Research on Experimental Animals of the North-West University (Potchefstroom campus). Male Sprague-Dawley rats were sacrificed by decapitation and the brain tissue was removed and preserved for homogenation. After homogenation, the aliquoted brain homogenate was stored at -70°C. An adapted method described by Salter & Knowles (1998) was employed for the determination of NOS activity by measuring the conversion of oxyHb to metHb. All materials were purchased from Sigma-Aldrich (UK) and Merck (St. Louis, MO, USA). Continuous scans of spectra were recorded using a Varian Cary-50 UV-Visible spectrophotometer. The slope values were calculated at specific wavelengths, utilising the software package, Cary Win-UV (version 3.00) and the IC\textsubscript{50} values were calculated from these inhibition data. All data analysis, calculation and graphs were done using Prism 4.02 (GraphPad, Sorrento Valley, CA).

5.2.1. Materials

The hemoglobin (0.144 mM) that mainly consists of metHb was firstly converted to its oxygenated form (Feelisch et al., 1996). This was achieved by gently dissolving the crystallised hemoglobin (20 mg) in distilled water (1.5 ml) and subsequent reduction with
sodium dithionate (2-3 fold molar excess). The solution immediately changed from brownish red (mixture of oxyHb and metHb) to a dark red (deoxyhemoglobin) colour after the reductant was added. Oxygenation was carried out by blowing 100% oxygen over the surface while the solution was gently swirled. The gradual colour change from dark red to bright red was indicative of the oxygenation of hemoglobin. Purification and desalting was performed by passing the resulting oxyHb solution through a Sephadex G-25 column. The oxyhemoglobin is eluted as a single bright-red band. The front and back edges of the band were discarded.

The concentration of the oxyHb was calculated by the method described by Feelish et al., 1996). 10 μl of the oxyHb stock solution was added to 2990 μl of HEPES buffer in a cuvette and the absolute absorbance at 415 nm was determined against a buffer blank. The concentration of oxyHb (c_{oxyHb}) was calculated according to eq. 5.2 from the mean absorbance (A_{m415 nm}) of three separate determinations using a molar extinction coefficient $E_{415(oxyHb)}$ of 131.0 mM$^{-1}$ cm$^{-1}$ (Van Assendelft, 1970).

$$c_{oxyHb} = \frac{A_{m415nm} \times 300 \text{ (dilution factor)}}{E_{415(oxyHb)}}$$  

Using the above equation, the final calculated oxyHb concentration of the stock solution was found to be 0.8 mM. The stock solution was then aliquoted in 200 μl units and stored at -70°C.

Potassium phosphate buffer (100 mM) was prepared at room temperature by mixing both the monobasic (KH$_2$PO$_4$, 300 ml; 100 mM) and the dibasic (K$_2$HPO$_4$, 1347 ml; 100 mM) solutions and adjusting the pH to 7.4 by adding either KH$_2$PO$_4$ or K$_2$HPO$_4$.

Calcium chloride solution (CaCl$_2$, 12.5 mM) was prepared in the potassium phosphate buffer and L-arginine (1 mM) and NADPH (5 mM) in water (Salter & Knowles, 1998).

The test compounds were dissolved in potassium phosphate buffer or methanol (MeOH; final incubation concentration 5 %) to give a series of final incubation concentrations ranging from 10 μM to 10 mM. 7-Nitroindazole was dissolved in MeOH and used as the positive control in final concentrations ranging from 10 μM to 10 mM.

The extraction buffer was prepared by dissolving sucrose (320 mM), HEPES (20 mM) and ethylenediaminetetra-acetic acid (EDTA; 1 mM) in distilled water and adjusting the pH to 7.2 at room temperature by adding 10 % HCl$_{aq}$ (Salter & Knowles, 1998).
following constituents were then added to the final concentrations indicated: D,L- 
dithiothreitol (DTT; 1 mM), leupeptin (10 μg/ml), soybean-trypsin inhibitor (10 μg/ml) and 
aprotinin (2 μg/ml). The extraction buffer was then made up to its final volume with 
distilled water and 50 ml aliquots were stored at -20°C until required.

Phenylmethylsulphonyl fluoride (PMSF; 10 mg/ml) was prepared as a separate solution 
in absolute ethanol and stored at -20°C. Because PMSF is unstable in aqueous solution, 
it is not included in the buffer at this stage, but only added to the extraction buffer during 
the extraction procedure.

5.2.2. Methods

5.2.2.1. Sample preparation

Extraction and storage of tissue samples prior to the assay were carried out at 0°C - 4°C 
to avoid loss of enzyme activity. Fresh rat brain was weighed in 50 ml pre-cooled Falcon 
tubes and placed on ice. After rinsing with ice cold extraction buffer, a measured volume 
of extraction buffer (5 ml/g tissue) was added to the tissue. The sample was then 
homogenised with a mechanical homogeniser while the temperature was maintained at 
4°C. After 10 seconds of homogenisation the PMSF (10 μM/ml of extraction buffer) was 
added to the mixture and homogenised for a further 30 seconds. The homogenate was 
then centrifuged at 12000 x g for 10 minutes to minimise turbidity. Once the supernatant 
was collected, it was divided into 2 ml aliquots which were assayed immediately or 
rapidly frozen and stored at -70°C.

5.2.2.2. Assay procedure

Oxyhemoglobin, CaCl₂ and L-arginine were diluted in the potassium phosphate buffer to 
give final concentrations of 1.44 μM, 250 μM and 1 mM respectively and to make up at 
least 80% of the final reaction mixture volume. The reaction mixture was prewarmed for 
three minutes to the required assay temperature of 37°C. After adding NADPH to a final 
concentration of 100 μM along with the test compound or control, the reaction was 
started by the addition of tissue extract (100 μl).

After establishing the baseline, continuous scans with a scan rate of 600 nm/min every 
12 seconds were recorded between 390 nm and 430 nm. The conversion of oxyHb to 
metHb was monitored over a period of 5 minutes (fig. 5.5).
5.2.3. Results and Discussion

From the continuous spectrophotometric scans, the slope value of the difference spectra between 401 nm and 421 nm were calculated and used as an index to determine NOS activity. Two of the recorded spectra of compound 4 are depicted in fig. 5.5 and fig. 5.6 and represents the control and 1 mM incubations respectively. Comparison of the two spectra revealed a marked change in absorbance at 401 nm, while the absorbance at 421 remained constant. The change in absorbance at 401 nm was used as an indication of the NOS inhibitory effect of compound 4.

A decrease in absorbance at 401 nm is indicative of a decrease in metHb formation and thus a decrease in enzyme activity. Enzyme activity is expressed as the rate at which NO (or metHb) is generated. The resulting slope value of the change in absorbance between two specific wavelengths (e.g. 401 nm and 421 nm) over time is representative of this conversion rate (fig. 5.4). Although there was no change in absorbance at 421 nm, the slope value was still deducted from the slope value at 401 nm to take other variables into consideration such as pH, temperature and concentration.

![Graph](image)

**Figure 5.5:** Spectrophotometric recordings of the control incubation (0 mM inhibitor). Recordings were monitored over a period of 5 minutes between 390 nm and 430 nm. Arrow at 401 nm and 421 nm indicate the change in absorbance (ΔA) over time.
Figure 5.6: Spectrophotometric recordings of NOS activity at a 1 mM concentration of compound 4. When compared to the spectra at 0 mM inhibitor (fig. 5.5), a marked change in absorbance can be seen. Arrow at 401 nm and 421 nm indicate the change in absorbance (ΔA) over time.

From the spectra depicted in fig. 5.5 and 5.6, the difference in the change of absorbance (ΔA) between 401 nm and 421 nm versus time was calculated by plotting the ΔA of the respective wavelengths against time (fig. 5.7 and 5.8). The resulting curves’ slope values (m_{ΔA(401 nm)} • m_{ΔA(421 nm)}) are indicative of the extent of oxyHb’s conversion to metHb and is directly proportional to the amount of NO generated and enzyme activity.

A decrease in enzyme activity is observed when the slope value of the control was compared to that of the 1 mM inhibitor concentration (table 5.1). The slope values of the curves are linear over the first four minutes and can also be used as an indication of NO formation (fig. 5.7 and 5.8).
**Figure 5.7:** Determination of the change in absorbance of the control incubation. (0 mM inhibitor; fig. 5.5). The change in absorbance at 401 nm and 421 nm versus time was calculated and the difference of the respective slope values ($m_{\Delta A(401\text{ nm})} - m_{\Delta A(421\text{ nm})}$) gives an indication of enzyme activity.

**Figure 5.8:** Determination of the change in absorbance with compound 4. (1 mM inhibitor; fig. 5.6). The difference in slope values ($m_{\Delta A(401\text{ nm})} - m_{\Delta A(421\text{ nm})}$) is representative of enzyme activity and in comparison with the control (fig. 5.7), indicates a decrease in enzyme activity with the addition of the novel inhibitor.
Table 5.1: Comparison of the resulting slope values of the control and 1 mM inhibitor incubation during the initial linear phase indicating a decrease in enzyme activity.

<table>
<thead>
<tr>
<th>Incubation</th>
<th>(m_{401\ nm})</th>
<th>(m_{421\ nm})</th>
<th>(m_{(421\ nm-421\ nm)})</th>
<th>% NOS activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control 1*</td>
<td>0.0110</td>
<td>0.0026</td>
<td>0.0084</td>
<td>-98.82</td>
</tr>
<tr>
<td>Control 2*</td>
<td>0.0157</td>
<td>0.0057</td>
<td>0.0100</td>
<td>-99.01</td>
</tr>
<tr>
<td>Control 3*</td>
<td>0.0159</td>
<td>0.0082</td>
<td>0.0077</td>
<td>-98.718</td>
</tr>
<tr>
<td>1 mM inhibitor 1*</td>
<td>0.0091</td>
<td>0.0053</td>
<td>0.0038</td>
<td>-44.47</td>
</tr>
<tr>
<td>1 mM inhibitor 2*</td>
<td>0.0099</td>
<td>0.0050</td>
<td>0.0049</td>
<td>-48.51</td>
</tr>
<tr>
<td>1 mM inhibitor 3*</td>
<td>0.0043</td>
<td>0.0010</td>
<td>0.0033</td>
<td>-42.31</td>
</tr>
</tbody>
</table>

* All incubations were done in triplicate and the data of control 1 and the incubation containing 1 mM inhibitor are depicted in fig. 5.7 and fig. 5.8.

During the initial linear phase (first four minutes), the enzyme activity of all test compound incubations were calculated as a percentage value of the control (incubations containing 0 mM inhibitor represents ~100 % activity). The corresponding dose response curves were obtained by plotting the inhibition data of enzyme activity against a series of logarithmic concentrations of the test compounds. The dose response curves of each experiment were calculated by dividing the resulting slope value through the slope value of the control and each experiment was conducted in triplicate. Data points are expressed as mean values with standard error of the mean.

The inhibition curves of selected compounds were superimposed on a single graph (fig. 5.12) and the calculated IC\textsubscript{50} value were compared (table 5.2). From the calculated IC\textsubscript{50} value; compounds 1, 3, 4, 5 revealed promising results as possible NOS inhibitors.
Figure 5.16: Inhibition curve of 7-NI on NOS activity. L-arginine (100 mM) was used as substrate. Log (IC₅₀): -4.981; IC₅₀: 1.04 x 10⁻⁵ M as indicated by the dotted line.

Figure 5.16: Inhibition curve of 3-(2-aminoethyl)indole on NOS activity. L-arginine (100 mM) was used as substrate. Log (IC₅₀): -2.692; IC₅₀: 2.03 x 10⁻³ M as indicated by the dotted line.
Figure 5.12: Inhibition curve of compound 1 on NOS activity. L-arginine (100 mM) was used as substrate. Log ($IC_{50}$): -3.207; $IC_{50}$: $6.21 \times 10^{-4}$ M as indicated by the dotted line.

Figure 5.14: Inhibition curve of compound 2 on NOS activity. L-arginine (100 mM) was used as substrate. No $IC_{50}$ value could be calculated due to solubility problems at 1 mM inhibitor concentration.
Figure 5.15: Inhibition curve of compound 3 on NOS activity. L-arginine (100 mM) was used as substrate. Log (IC₅₀): -3.255; IC₅₀: 5.56 x 10⁻⁴ M as indicated by the dotted line.

\[
\log \text{IC₅₀} = -3.255 \\
\text{IC₅₀} = 5.56 \times 10^{-4} \text{ M}
\]

Figure 5.9: Inhibition curve of compound 4 on NOS activity. L-arginine (100 mM) was used as substrate. Log (IC₅₀): -3.025; IC₅₀: 9.44 x 10⁻⁴ M as indicated by the dotted line.

\[
\log \text{IC₅₀} = -3.025 \\
\text{IC₅₀} = 9.44 \times 10^{-4} \text{ M}
\]
**Figure 5.13:** Inhibition curve of compound 5 on NOS activity. L-arginine (100 mM) was used as substrate. Log (IC$_{50}$): -3.409; IC$_{50}$: 3.9 x 10$^{-4}$ M as indicated by the dotted line.

**Figure 5.10:** Inhibition curve of compound 19 on NOS activity. L-arginine (100 mM) was used as substrate. Log (IC$_{50}$): -2.345; IC$_{50}$: 4.51 x 10$^{-3}$ M as indicated by the dotted line.
Biological evaluation: Chapter 5

Figure 5.11: Inhibition curve of compound 21 on NOS activity. L-arginine (100 mM) was used as substrate. Only a 10% inhibition was observed and no IC_{50} value could be calculated.

Figure 5.17: Superimposed inhibitory curves of test compounds with meaningful IC_{50} values. At 125 μM compound 1 and 5 already showed a 15% inhibition, but compound 3 and 4 only showed the same amount of inhibition at 250μM and 400μM, respectively.
Table 5.2: Summary of the test compounds with their corresponding IC\(_{50}\) values.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Log(IC(_{50}))</th>
<th>IC(_{50})(M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><img src="image1" alt="Structure 1" /></td>
<td>-3.207</td>
<td>6.21 \times 10^{-4}</td>
</tr>
<tr>
<td>2</td>
<td><img src="image2" alt="Structure 2" /></td>
<td>Solubility problems</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td><img src="image3" alt="Structure 3" /></td>
<td>-3.255</td>
<td>5.56 \times 10^{-4}</td>
</tr>
<tr>
<td>4</td>
<td><img src="image4" alt="Structure 4" /></td>
<td>-3.025</td>
<td>9.44 \times 10^{-4}</td>
</tr>
<tr>
<td>5</td>
<td><img src="image5" alt="Structure 5" /></td>
<td>-3.409</td>
<td>3.9 \times 10^{-4}</td>
</tr>
</tbody>
</table>
From the results it is clear that in the series of compounds evaluated, only the compounds containing an indole moiety, 1, 2, 3, 4 and 5 show promising NOS inhibition. Comparison of the IC₅₀ values of the test compounds and 7-NI revealed that although the novel compounds are less potent than 7-NI, it showed promising results as NOS inhibitors with sub millimolar potency.

### 5.3. Lipid peroxidation

#### 5.3.1. Introduction

Reactive oxygen species (ROS) are produced in the course of normal metabolism and these serve important physiological functions. When high levels of ROS exceeds the normal needs of the cell, it may indiscriminately damage the latter's structural and functional integrity either by directly modifying cellular DNA, proteins, and lipids or by initiating chain reactions that can bring about extensive oxidative damage to these critical molecules (Cui et al., 2004). Although the human body possess endogenous antioxidants such as α-tocopherol and melatonin against ROS, it can sometimes be

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC₅₀ Value</th>
<th>Potency</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>-2.345</td>
<td>4.51 X 10⁻³</td>
</tr>
<tr>
<td>21</td>
<td></td>
<td>Only 10 % inhibition observed</td>
</tr>
<tr>
<td>7-NI</td>
<td>-4.981</td>
<td>1.04 X 10⁻⁵</td>
</tr>
<tr>
<td>3-(2-amino-ethyl)indole</td>
<td>-2.692</td>
<td>2.03 X 10⁻³</td>
</tr>
</tbody>
</table>
inadequate, leading to oxidative stress where the production of ROS exceeds the antioxidant defences of the organism.

Although cells possess an intricate network of defence mechanisms to neutralise excess ROS and reduce oxidative stress, some tissues, especially the brain, are much more vulnerable to oxidative stress because of their elevated consumption of oxygen and the consequent generation of large amounts of ROS. For the same reason, the mitochondrial DNA (mtDNA) of brain cells is highly susceptible to structural alterations resulting in mitochondrial dysfunction. Several lines of evidence strongly suggest that these effects of ROS may be etiologically related to a number of neurodegenerative disorders (Cui et al., 2004).

ROS is a collective term that includes all reactive forms of oxygen, including both the radical and nonradical species that participate in the initiation or propagation of radical chain reactions. Singlet oxygen is a very reactive ROS and induces various effects through its action on polyunsaturated fatty acids (PUFAs) and DNA. When molecular oxygen is reduced to water in the electron transport chain, there is a stepwise addition of four electrons, resulting in the formation of several hydrogen-containing ROS, such as hydroperoxyl radical, superoxide radical, hydrogen peroxide, and the hydroxyl radical (Table 5.3; Cui et al., 2004).

Table 5.3: Formation of ROS by reduction of molecular oxygen in the electron transport chain.

<table>
<thead>
<tr>
<th>Step</th>
<th>Reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i)</td>
<td>$\text{O}_2 + e^- + H^+ \rightarrow \text{HO}_2$ (hydroperoxyl radical)</td>
</tr>
<tr>
<td>(ii)</td>
<td>$\text{HO}_2 \rightarrow H^+ + \text{O}_2^-$ (superoxide radical)</td>
</tr>
<tr>
<td>(iii)</td>
<td>$\text{O}_2^- + 2H^+ + e^- \rightarrow \text{H}_2\text{O}_2$ (hydrogen peroxide)</td>
</tr>
<tr>
<td>(iv)</td>
<td>$\text{H}_2\text{O}_2 + e^- \rightarrow \text{OH}^- + \text{OH}$ (hydroxyl radical)</td>
</tr>
<tr>
<td>(v)</td>
<td>$\text{OH}^- + e^- + \text{H}^+ \rightarrow \text{H}_2\text{O}$</td>
</tr>
<tr>
<td>(vi)</td>
<td>$\text{O}_2^- + \text{H}_2\text{O}_2 \rightarrow \text{OH}^- + \text{OH} + \text{O}_2$ (Haber - Weiss reaction)</td>
</tr>
<tr>
<td>(vii)</td>
<td>$\text{Fe}^{2+} + \text{H}_2\text{O}_2 \rightarrow \text{OH}^- + \text{OH} + \text{Fe}^{3+}$ (Fenton reaction)</td>
</tr>
</tbody>
</table>
There are several observations suggesting that the brain may be particularly vulnerable to these ROS (Reiter, 1995; Olanow, 1993; Muller, 1997; Halliwell, 2001). Some of the most important of these are summarised below:

- The brain consumes a fifth of the total oxygen inspired and carries out the turnover of large quantities of ATP at a high rate. Since approximately 5% of oxygen consumed by cells is estimated to be reduced to ROS, relatively higher amounts of ROS may be generated in the brain as compared to other tissues that use less oxygen.

- Brain is rich in PUFAs, which are particularly susceptible to ROS damage.

- The release of excitatory neurotransmitters, such as glutamate, induces a cascade of reactions in the postsynaptic neuron, resulting in the formation of ROS. Depending on the density of such neurons, this could cause localised lesions in the nervous system.

- The liberation of ROS during the oxidation of dopamine by monoamine oxidase in the nerve terminals of dopaminergic neurons may produce increased oxidative stress in brain regions, such as substantia nigra. This is suggested to have a causative role in the etiology of PD.

- The brain contains almost no catalase and less glutathione peroxidase and vitamin E, when compared to liver.

- An endogenous antioxidant produced in the pineal gland, called melatonin, is found to be a good scavenger of ROS, but its concentration decreases markedly with age.

5.3.2. Experimental procedures

A study protocol was approved by the Ethics Committee for Research on Experimental Animals of the North-West University (Potchefstroom campus). Male Sprague-Dawley rats were sacrificed by decapitation and the brain tissue was removed and preserved for homogenation. All materials were purchased from Sigma-Aldrich (UK) and Merck (St. Louis, MO, USA). A modified version of the thiobarbituric acid (TBA) assay of Ottino & Duncan (1996) was used to screen test compounds at a concentration of 1 mM for lipid peroxidation. Detection of lipid peroxidation relies on the on the bases of the complex formation between malondialdehyde (MDA) and TBA (fig. 5.18), generating a pink coloured complex that was spectrophotometrically measured at 532 nm.
Figure 5.18: Reaction between MDA and TBA.

The formed MDA is used as an estimation of the degree of lipid peroxidation in the assay.

5.3.3. Assay procedure

Sprague-Dawley rats (± 250 g) were sacrificed by decapitation and the brain tissue was removed and preserved for homogenation. Excessive blood was removed by rinsing the tissue with phosphate-buffered saline (PBS), that consisted of 137 mM NaCl, 2.7 mM KCl, 10 mM K$_2$HPO$_4$ and 2 mM KH$_2$PO$_4$ at pH 7.4. The brain tissue, weighing between 1.6 and 2 g were homogenised in phosphate-buffered saline to give a final homogenate solution of 10 %. Homogenate preparation was carried out on ice. All the samples were prepared by adding 800 μl of the 10 % homogenate in test tubes and subsequently 200 μl PBS for the control and 100 μl PBS for all test compounds to give a final volume of 1 ml. 50 μl Hydrogen peroxide (5 mM) was used as a toxin to generate hydroxyl radicals and initiate lipid peroxidation in the rat brain homogenates. 25 μl Iron(III)chloride (4.88 mM) and 25 μl ascorbic acid (1.4 mM) were used to increase the generation of hydroxyl radicals (Table 5.4).

Table: 5.4: Composition of test tubes prior spectrophotometric analysis.

<table>
<thead>
<tr>
<th>Test tubes</th>
<th>Homogenate (10%)</th>
<th>PBS</th>
<th>H$_2$O$_2$ (5 mM)</th>
<th>FeCl$_3$ (4.88 mM)</th>
<th>Vit. C (1.4 mM)</th>
<th>Compound</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Control</td>
<td>0.8</td>
<td>0.2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>b) 1</td>
<td>0.8</td>
<td>0.1</td>
<td>0.05</td>
<td>0.025</td>
<td>0.025</td>
<td>0.1</td>
</tr>
<tr>
<td>c) 2</td>
<td>0.8</td>
<td>0.1</td>
<td>0.05</td>
<td>0.025</td>
<td>0.025</td>
<td>0.1</td>
</tr>
<tr>
<td>d) 3</td>
<td>0.8</td>
<td>0.1</td>
<td>0.05</td>
<td>0.025</td>
<td>0.025</td>
<td>0.1</td>
</tr>
<tr>
<td>e) 4</td>
<td>0.8</td>
<td>0.1</td>
<td>0.05</td>
<td>0.025</td>
<td>0.025</td>
<td>0.1</td>
</tr>
<tr>
<td>f) 5</td>
<td>0.8</td>
<td>0.1</td>
<td>0.05</td>
<td>0.025</td>
<td>0.025</td>
<td>0.1</td>
</tr>
<tr>
<td>g) 19</td>
<td>0.8</td>
<td>0.1</td>
<td>0.05</td>
<td>0.025</td>
<td>0.025</td>
<td>0.1</td>
</tr>
<tr>
<td>h) 21</td>
<td>0.8</td>
<td>0.1</td>
<td>0.05</td>
<td>0.025</td>
<td>0.025</td>
<td>0.1</td>
</tr>
</tbody>
</table>
All test compounds were dissolved in DMSO to give concentrations of 10 mM and further diluted to a concentration of 1 mM for incubation. The test tubes were vortexed and kept on ice. After incubation at 37°C for 60 minutes in an oscillation water bath, the turbid solutions were centrifuged at 2000 x g for 20 minutes. The clear supernatant was transferred to clean test tubes. Before 0.5 ml butylated hydroxytoluene (0.5 g/l; BHT), 1 ml trichloroacetic acid (10 %; TCA) and 0.5 ml 2-thiobarbituric acid (0.33 %; TBA) were added to the mixture. The newly prepared test tubes were vortexed again and incubated for another 60 minutes at 60°C. After cooling on ice, 2 ml butanol was added to each test tube before it was vortexed and centrifuged again for 10 minutes at 2000 x g. The organic phase was transferred to clean cuvettes and analysed with a Milton Roy spectronic 1201 spectrophotometer at 532 nm with butanol used as the blanco. Trolox (10 mM), a known antioxidant, was used as a standard. The values were expressed as nmol MDA equivalents per mg tissue.

5.3.4. Results and Discussion

The adopted method was tested by inducing free radical generation with a known free radical generator, hydrogen peroxide, in rat brain homogenate. Hydrogen peroxide produced a marked increase in lipid peroxidation (Table 5.5). Therefore, the modified method could be used to determine lipid peroxidation in biological samples, with satisfactory results.

Table 5.5: Concentration-dependent effect of hydrogen peroxide on lipid peroxidation in rat brain homogenate.

<table>
<thead>
<tr>
<th>Hydrogen peroxide concentration (mM)</th>
<th>Malondialdehyde (nmol per mg tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.0054</td>
</tr>
<tr>
<td>0.1</td>
<td>0.0243</td>
</tr>
<tr>
<td>0.5</td>
<td>0.0251</td>
</tr>
<tr>
<td>1</td>
<td>0.0274</td>
</tr>
</tbody>
</table>

As shown in table 5.5, exposure of rat brain homogenate to various concentrations (0 – 1 mM) of hydrogen peroxide (H₂O₂) increased lipid peroxidation in a concentration-
Biological evaluation: Chapter 5

dependent manner. All test tubes were treated with 0.5 mM H$_2$O$_2$ to initiated lipid peroxidation.

Materials of animal origin usually contain large amounts of protein, to which malondialdehyde may be bound (Draper & Hadley 1990). It is therefore imperative to release the protein-bound malondialdehyde by adding trichloroacetic acid and subsequently heating the mixture.

It is also important to prevent adsorption of the thiobarbituric acid-malondialdehyde complex onto insoluble protein. This is facilitated by the removal of any solid material by centrifugation.

The malondialdehyde levels (nmol per mg tissue) were obtained from a calibration curve (fig. 5.19). Regression analysis showed that concentration and absorbance were linear with a regression value of 0.9997. Each point on the calibration curve was based on triplicate determinations.

![Graph](image)

Figure 5.19: Calibration curve for the detection of lipid peroxidation.

The recorded absorbance values of the test compounds were substituted into the linear regression equation (eq. 5.2) obtained from the calibration data.
The recorded absorbance values were divided by 0.8 to determine the amount MDA per mg tissue. Comparison of these data with trolox can be expressed in nmol MDA per mg tissue (fig. 5.20). All the test compounds except compound 8, 21 revealed promising antioxidant activity when compared with trolox.

![Test compounds]

**Figure 5.20:** Antioxidant capacity of test compounds in comparison with trolox, a known antioxidant.

### 5.4. Conclusion

The series of compounds were evaluated for NOS and anti-oxidative activity. Compounds 1, 2, 3, 4 and 5 showed promising results as NOS inhibitors. Comparison of the IC$_{50}$ values of the test compounds and 7-NI revealed that although they were less potent than 7-NI, it still showed promising results as NOS inhibitors. The novel compounds 1, 2, 3, 4 and 5 also had excellent anti-oxidative properties when compared to trolox. The polycyclic cage structure that was applied as carrier molecule, thus not only serve as pharmacokinetic enhancer but also to improve pharmacodynamics. With the cage...
Biological evaluation: Chapter 5

structures' described calcium channel activity and taking the above aspects into account, these novel compounds may find application as multipotent drugs in neuroprotection.
6. Introduction

Designing drugs with multifunctional modes of action has received much attention lately (Van der Schyf et al., 2006). For this reason a compound that acts as calcium channel blocker, NOS inhibitor and free radical scavenger may be of value in the quest for neuroprotective drugs. We therefore decided to synthesise a series of pentacycloundecyl derivatives with known Ca\(^{2+}\) channel activity (Geldenhuys et al., 2003a Van der Schyf et al., 1986; Van der Walt et al., 1988), incorporating an indole moiety (compounds 1, 2, 3, 4 and 5) for which anti-oxidant and NOS activity has been described (Chang et al., 2000).

Computer modelling, synthesis and biological evaluation of the novel compounds were performed to determine their potential as neuroprotective drugs.

6.1. Molecular modelling

Molecular modelling was performed on a series of polycyclic indole derivatives to identify potential drug candidates for nitric oxide synthase (NOS) as the target. A docking study utilising Catalyst 4.9\(^{\circ}\) and the Ligandfit module of Cerius\(^{2}\) was performed to achieve this. A crystallised nNOS structure (1OM5) was retrieved from the RCSB Protein Data Bank, the active site was identified and the novel series of compounds was docked into the active site using Ligandfit\(^{\circ}\). The DREIDING2.21 force field and Gasteiger charges were used throughout the experiment and all other values were set to default. After completing the docking procedure, hydrogen bonds were calculated to identify possible conformations for favourable interactions.

In all the cases the indole ring was oriented towards the heme moiety and the cage structure located near the entrance cavity. Compounds 1, 3, 4, 5, 6, 7, 9, 11, 12, 13, 16, 17, 18, 19 formed hydrogen bonds with essential amino acid residues Tpr587, Glu592 and heme. Compounds 2, 8, 10, 14, 15 formed bonds to Tyr 588, Gln 478 and Asp 597, amino acids only play a role in the stabilisation and orientation of ligands in the cavity. The molecular modelling study clearly suggests that selected compounds will form hydrogen bond interactions with the amino acids and heme essential for substrate binding and thus have the potential to interact and inhibit the NOS enzyme.
6.2. Synthesis

High yields of the Cookson diketone (Cookson et al., 1964) were obtained from ultraviolet irradiation of the p-benzoquinone-cyclopentadiene adduct. The monoketone was synthesised from diketone to restrict the reaction to only one ketone group. Both these pentacycloundecyl structures were used as intermediates in further amination reactions. A series of polycyclic indole derivatives were synthesised by reductive amination of the monoketone and diketone structures.

Various linkers were to be applied between the cage structures and the indole moiety, but due to multiple reactions and rearrangements of the cage structures, no amides, ethers or esters could be obtained. Five novel tryptamine compounds were synthesised with percentage yields varying between 33.6 % and 88.3 %. Flash column chromatography was mostly used in the purification of the compounds. Other methods applied included recrystallisation and acid-base extractions. Seven compounds were adequately purified and characterised for biological evaluation.

6.3. Biological evaluation

The selected compounds were tested for NOS activity and antioxidant capacity. An in vitro oxyhemoglobin (oxyHb) assay was employed to determine NOS activity of the novel compounds. This assay is based on the reaction between NO and oxyHb with the subsequent formation of methemoglobin (methHb). NO formation and thus NOS activity could be obtained by measuring the change in absorbance (ΔA) during the conversion of oxyHb to methHb.

Of the newly synthesised compounds, structures 1, 4, 3, 5 demonstrated meaningful NOS inhibition in the micromolar range. Solubility problems were observed during biological testing of compound 2 and no IC₅₀ value could be calculated.

The indole moiety was compared with aminoguanidine (a known selective NOS inhibitor) to see if there is a resemblance. From this comparison a conclusion was drawn that the unsaturated amine moiety might be an important pharmacophoric entity for effective NOS inhibition (fig 6.1)
The dose response curves of the individual compounds compared well with cage guanidine structures (Wilkes, 2005), although it proved to be less potent than 7-NI.

The test compounds were also screened for antioxidative properties. An adapted method of Ottino & Duncan (1996) was used for the detection of lipid peroxidation. This process is based on the formation of a complex between malondialdehyde (MDA) and thiobarbituric acid (TBA), resulting in a pink coloured complex that can be spectrophotometrically analysed at 532 nm.

Hydrogen peroxide was used as a free radical generator and trolox, a known antioxidant, was used as standard reference. Of the newly synthesised compounds, all the tryptamine compounds possessed excellent antioxidative properties when compared with trolox. The indole moiety probably plays an important role in this activity.

6.4. Conclusion

The urgent need of selective nNOS inhibitors are of great importance in the treatment of neurodegenerative disorders. Considering that NOS is primarily activated by the NMDA receptor, the combination of three properties (calcium channel blocking, selective NOS inhibition and antioxidative capacity) makes these novel compounds excellent drugs for possible treatment of neurodegenerative disorders.

The results obtained in this study clearly indicate the potential of these novel indole cage structures as NOS inhibitors and anti-oxidants. With the cage structures' described calcium channel activity and taking the above aspects into account, these novel compounds may find application as multipotent drugs in neuroprotection.

In conclusion, the aim of this study to design and evaluate a novel series of polycyclic indole derivatives for NOS and antioxidant activity was achieved and the results obtained gave some insights for future investigation. These should include further...
Summary, discussion and conclusion: Chapter 6

optimisation of the indole and cage structures and their synthesis as well as NOS isoform selectivity studies.
7. Bibliography:

8. References:


Bibliography


Bibliography


Bibliography


Bibliography


Bibliography


Bibliography


Bibliography


inhibit basal but not agonist-stimulated release of nitric oxide in rat aorta.  

*Experimental Neurology*, 149:1-12.


*Neuron*, 20:633-647.


*Proceedings of the National Academy of Sciences of the United States of America*, 88:10480-10484.

*Journal of Comparative Neurology*, 378:70-87.


Bibliography


Bibliography


- Infrared spectroscopy
- Mass spectrometry
- $^1$H nuclear magnetic resonance spectrometry
- $^{13}$C magnetic resonance spectrometry
Annexure 1

Spectral data

Spectrum 1: Mass spectrometry of 1.

Spectrum 2: $^1$H NMR of 1.
Annexure 1

Spectral data

Spectrum 3: $^{13}$C NMR of 1.

Spectrum 4: $^1$H NMR of 2.
Spectrum 5: $^{13}$C NMR of 2.

Spectrum 6: Mass spectrometry of 3.
Annexure 1 Spectral data

Spectrum 7: $^1$H NMR of 3.

Spectrum 8: $^{13}$C NMR of 3.
Annexure 1

Spectral data


Spectrum 10: Mass spectrometry of 4.
Annexure 1

Spectral data

Spectrum 11: $^1$H NMR of 4.

Spectrum 12: $^{13}$C NMR of 4.

Spectrum 14: Mass spectrometry of 5.
Spectrum 15: $^1$H NMR of 5.

Spectrum 16: $^{13}$C NMR of 5.
Annexure 1 Spectral data

Spectrum 17: Infrared absorption spectrum of 19.

Spectrum 18: Mass spectrometry of 19.
Annexure 1

Spectral data

Spectrum 19: $^1$H NMR of 19.

Spectrum 20: $^{13}$C NMR of 19.
Annexure 1

Spectral data


Spectrum 23: $^1\text{H NMR}$ of 21.

Spectrum 24: $^{13}\text{C NMR}$ of 21.
1. I would like to thank the Lord for His blessing and grace and for granting me the ability and opportunity. All the praise to Him.

2. A special thanks to my study leader, Prof. S.F. Malan; my co-study leader, Prof. D.W. Oliver for your assistance and motivation. Without you, this study would not have been possible.

3. My parents, Henk and Marie Oets and brothers – thank you for all your prayers and support. I'm proud to have you as my parents.

4. My beautiful wife, Stephanie – thank you for your support, love and motivation.

5. Dennis Wilkes for his guidance with the NOS assay.

6. A special word of thanks to Prof Mino R Caira, University of Cape Town, Department of Chemistry for the x-ray analysis.

7. Melanie van Heerden and Nellie Scheepers for their guidance and help with the lipid peroxidation assay.

8. Dr. Jacques Petzer for his enthusiasm for chemistry and always willing to help.

9. My lab partner, Louis Prins, for listening and motivation.

10. A. Joubert and J. Jordaan for their help with the MS and NMR analysis.

11. CENQAM for the use of their laboratory and spectrophotometer.

12. The National Research Foundation for financial support.

13. Kagisho Sempe for always being friendly and helping with chemicals.

14. Mr. Cor Bester of the Animal Research Centre at North-West University (Potchefstroom Campus) for your assistance in handling and care of the animals.

15. The Department of Pharmaceutical Chemistry and all personnel for friendliness and support.
I would like to thank the Lord for His blessing and grace and for granting me the ability and opportunity. All the praise to Him.

A special thanks to my study leader, Prof. S.F. Malan; my co-study leader, Prof. D.W. Oliver for your assistance and motivation. Without you, this study would not have been possible.

My parents, Henk and Marie Oets and brothers – thank you for all your prayers and support. I'm proud to have you as my parents.

My beautiful wife, Stephanie – thank you for your support, love and motivation.

Dennis Wilkes for his guidance with the NOS assay.

A special word of thanks to Prof Mino R Caira, University of Cape Town, Department of Chemistry for the x-ray analysis.

Melanie van Heerden and Nellie Scheepers for their guidance and help with the lipid peroxidation assay.

Dr. Jacques Petzer for his enthusiasm for chemistry and always willing to help.

My lab partner, Louis Prins, for listening and motivation.

A. Joubert and J. Jordaan for their help with the MS and NMR analysis.

CENQAM for the use of their laboratory and spectrophotometer.

The National Research Foundation for financial support.

Kagisho Sempe for always being friendly and helping with chemicals.

Mr. Cor Bester of the Animal Research Centre at North-West University (Potchefstroom Campus) for your assistance in handling and care of the animals.

The Department of Pharmaceutical Chemistry and all personnel for friendliness and support.